

CURRICULUM VITAE
Daniel A. Pollyea, MD, MS

Current Position Professor of Medicine
 Clinical Director of Leukemia Services
 Robert H. Allen MD Endowed Chair in Hematology Research
 Interim Chief, Division of Hematology
 Department of Medicine
 University of Colorado School of Medicine

Office Address 1665 Aurora Court
 Room 4332, MS F704
 Aurora, CO 80045

Email daniel.pollyea@ucdenver.edu

Education and Postgraduate Training

1995 – 1999 Indiana University, Bloomington, IN (Highest Distinction): BS, Biology
1999 – 2003 University of Chicago Pritzker School of Medicine: MD
2003 – 2006 University of Chicago Hospitals: Internal Medicine
 Internship/Residency
2006 – 2007 Cook County Hospital, Chicago, IL: Chief Medical Resident
2007 – 2010 Stanford University: Fellow, Hematology/Oncology
2010 – 2011 Stanford University: MS, Epidemiology

Academic Appointments

2010 – 2011 Stanford University: Instructor, Hematology/Oncology
2011 – 2016 Assistant Professor, University of Colorado School of Medicine
 • Division of Hematology
 • Blood Cancer and Bone Marrow Transplantation Program
2011 – Present Clinical Director of Leukemia Services, University of Colorado
2016 – Present Associate Professor, University of Colorado School of Medicine, Division
 of Hematology
2022 – Present Professor, University of Colorado School of Medicine, Division of
 Hematology
2023 – 2024 Associate Chief of Clinical Affairs, Division of Hematology, University of
 Colorado School of Medicine
2024 – Present Interim Division Chief, Hematology

Professional Positions, Organizations and Committees

Hospital

2011 – Present University of Colorado Clinical Director of Leukemia Services
 University of Colorado Cancer Center Scientific Review Committee
2011 – 2014 (Protocol Review and Monitoring System)

2012 – 2022	University of Colorado Hospital Pharmacy and Therapeutics Committee Member
2012 – 2017	Hematology/Oncology Fellowship Selection Committee
2014 – 2016	Internal Medicine Residency Candidate Committee
2015 – 2019	Cancer Center Data Safety Monitoring Committee
2015 – 2017 +	Medical Director, Hematology Clinical Trials Unit
2019 – Present	
2021 – Present	Clinical Trials Mentor, Hematology Clinical Trials Unit
2016 – 2019	University of Colorado Department of Medicine Annual Research Day Planning Committee
2020 – 2022	University of Colorado Cancer Center Investigator Initiated Trials Committee
2021	Gates Biomanufacturing Facility Executive Director Search Committee
2021	Cancer Center Hispanic Outreach Committee
2022	Oncology Clinical Outcomes Governance Group Committee Member
2023 – Present	PSTP Selection Committee Member

Non-Hospital (Regional, National and International)

2011 – 2013	Southwest Oncology Group, Leukemia Committee Member
2012 – 2020	Leukemia and Lymphoma Society Rocky Mountain Chapter Board of Trustees
2012 – 2017	American Society of Hematology Committee on Government Affairs
2013 – Present	National Comprehensive Cancer Network, Acute Myeloid Leukemia Committee Member
2019 – 2021	Vice-Chairman
2021 – Present	Chairman
2013 – 2020	National Comprehensive Cancer Network, Myelodysplastic Syndromes Committee Member
2014, 2022	Cancer League of Colorado, Scientific Advisory Board
2014 – 2015	Leukemia and Lymphoma Society of Canada, Scientific Advisory Board
2015 – 2017	National Comprehensive Cancer Network, Myeloproliferative Neoplasms Committee Member (founding member)
2018 – 2020	American Society of Hematology Working Group on Innovations in Clinical Trials
2019 – Present	National Cancer Institute Precision Medicine Initiative Working Group on Older Acute Myeloid Leukemia
2019 – 2024	American Society of Hematology Scientific Committee on Myeloid Neoplasia
2020 – 2022	American Society of Hematology Subcommittee on Clinical Trials
2021	The Boston Society AML 2021 Steering Committee
2021 – Present	Leukemia and Lymphoma Society Therapy Acceleration Program Committee
2021 – Present	Acute Leukemia Forum Annual Meeting Co-Chairman
2025	International Scientific Committee, Acute Leukemias Meeting, Munich, Germany

Honors, Special Recognitions and Awards

1996 – 1999	Indiana University Founder's Day Award (Dean's list)
1996 – 1999	Indiana University Biology Undergraduate Scholarship and Research Grant
1996	Golden Key National Honor Society
1998	Phi Beta Kappa
1999	Indiana University Fox Glen Research and Education Fund Award for Outstanding Undergraduate Research
1999	Outstanding Senior Student, Department of Biology, Indiana University
2001	American Pediatric Society Medical Student Research Award
2002	Calvin Fentress Senior Medical Student Research Fellow
2004	American Society of Hematology Annual Meeting Travel Award
2004, 2005	University of Chicago Department of Medicine Housestaff Scientific Session Presenter
2008	American Society of Hematology Clinical Research Training Institute (CRTI) Participant, Dana Point, CA
2008-2010	Stanford Hematology/Oncology Annual Retreat Oral Presenter
2009	Stanford Center for Clinical and Translational Education and Research (SCCTER) Intensive Course in Clinical Research
2010	White House Fellowship Regional Finalist
2010	Stanford Clinical and Translational Research Networking Program
2011	American Society of Clinical Oncology Annual Meeting Merit Award American Society of Hematology/European Hematology Association
2013	Translational Research Training in Hematology (TRTH) Workshop Participant, Milan, Italy
2013	Expert physician consultant, Grand Rounds virtual consultation service
2014 – Present	Clinical Innovation Award, Division of Hematology
2014	Gahanna Lincoln High School Hall of Fame Inductee
2015 – 2020	University of Colorado Department of Medicine Outstanding Early Career Scholar Awardee
2015	Conquer Cancer Foundation Scientific Career Development Retreat Participant
2018	Leukemia and Lymphoma Society Rocky Mountain Chapter "Chairman's Quality of Life Award"
2018 – Present	Robert H. Allen MD Endowed Chair in Hematology Research
2019 – Present	Vice Chair of the National Comprehensive Cancer Network AML Guidelines Committee
2021 – Present	Chair of the National Comprehensive Cancer Network AML Guidelines Committee
2023	Top reviewer, <i>Blood</i>
2024	The Leukemia and Lymphoma Society's Career Development Program Scholar in Clinical Research Achievement Award
2024	Clarivate Highly Cited Researcher: One of 6,636 worldwide and one of four at University of Colorado. "The rigorous evaluation and selection

process draws on data from the Web of Science Core Collection citation index, together with qualitative analysis performed by experts at the ISI at Clarivate”

Licensure and Board Certification

- Board certified in Internal Medicine 2006, recertification in 2016
- Board certified in Hematology 2010, recertification in 2023
- Board certified in Oncology 2011, recertification in 2021
- Colorado state medical license (2011)
- National Provider Number 1801915822
- State and Federal controlled substance licenses

Patents

PCT/US2020/021464: Methods of Detecting and Treating Venetoclax-Resistant Acute Myeloid Leukemia

Patent Application (Serial) No.: 17/435,728

Reference: CU5124H-US1

Cooley Reference: UNCO-025/N01US 300978-2165

Biomarker Detection Engine(s) For Predicting Treatment Outcomes for Patients Diagnosed with Myeloid Malignancies

Provisional, No. 63/715,721

SRSS Ref: 303.0138P

Review and Referee Work

- | | |
|-------------|--|
| 2011 | American Society of Hematology Annual Meeting Oral Session Moderator for Section: “Cytogenetics and Molecular Markers in Diagnosis and Prognosis: New Approaches to Personalized Therapy in Leukemia” |
| 2014 – 2016 | Leukemia and Lymphoma Society of Canada Annual Grant Reviewer |
| 2014 | American Society of Hematology Annual Meeting Oral Session Moderator for Section: “Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Molecular Targets and Drug Sensitivity in Myeloid Diseases” |
| 2014 | American Society of Hematology Annual Meeting Abstract Reviewer |
| 2014 | Cancer League of Colorado Grant Selection Committee |
| 2014 | American Society of Hematology Self-Assessment Program |
| 2014-2015 | American Society of Hematology Education Program |
| 2015-2017 | Data Safety Monitoring Board member and chair, Glycomimetics Protocol GMI-1271-201, “A Phase I/II, Open-Label Multicenter Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia” |

2015	National Comprehensive Cancer Network Young Investigator Award Grant Review Panelist for University of Colorado applicants
2016	American Society of Hematology Annual Meeting Oral Session Moderator for Section: "Acute Myeloid Leukemia: Clinical Studies: New Drugs for Older AML"
2017	United Kingdom Medical Research Council Clinical Scientist Fellowship Award reviewer
2017	American Society of Hematology Annual Meeting Abstract Reviewer
2017	American Society of Hematology Annual Meeting Oral Session Moderator for Section "Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance"
2017 – 2018	Rising Tide Foundation for Clinical Cancer Research and Leukemia and Lymphoma Society Prevention Research Grant Review Committee
2017 – Present	Independent Response Review Committee Chairman, Tolero Clinical Trial, TPI-ALV-201
2017 – Present	Leukemia and Lymphoma Society of Canada Blood Cancer Expert Reviewer Committee
2018	External reviewer for the University of Miami Miller School of Medicine promotion committee
2018	Leuka Leukemia Research Foundation (UK) Grant Review Committee
2018 – 2023	Data Safety Monitoring Board Chairman for Glycomimetics Protocol No. GMI-1271-301, A Phase III, Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2019	Austrian Science Fund Grant Reviewer
2019	Australian Academy of Science Fellowship Candidate Reviewer
2020	Chair, Independent Review Committee for clinical protocol "A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax and Azacitidine versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed AML who are Unfit for Intensive Chemotherapy."
2020 – 2021	Independent Review Committee Chairman for Takeda Study Pevonedistat 2002
2021	NCCN Oncology Research Program: Decitabine and Cedazuridine Request for Proposals Development Team
2021	Data Safety Monitoring Board Chairman for Abbvie Study M19-747
2022	Scientific Advisory Board, Cancer League of Colorado Data Safety Monitoring Board member, Aptevo 5001 Study: Phase 1/1B open-label, dose-escalation study of APV0436 in patients with relapsed or refractory AML or high-grade MDS
2023	Acute myeloid leukemia session co-chair, Society of Hematologic Oncology annual meeting

2024	Leukemia and Lymphoma Society Career Development Program Grant Review Committee
2024	National Cancer Institute Special Emphasis Panel R21 and R03 Grant Review Committee for PAR 22-216 and PAR 23-058
2024 – Present	Data Safety Monitoring Board Chair, Ryvu River-52 Clinical Trial
2024	Reviewer, Swiss National Science Foundation grant application program
2024	Leukemia and Lymphoma Society Academic Clinic Trial grant review panel member (leukemia section chair)
2025	Leukemia and Lymphoma Society Career Development Program Grant Review Committee, Chair

Reviewer at Large:

- Bone Marrow Transplantation
- Blood
- Annals of Internal Medicine (designated “Outstanding Reviewer” 2010)
- Annals of Oncology
- Journal of Clinical Oncology
- The Oncologist
- Haematologica
- Leukemia & Lymphoma
- Leukemia
- Public Library of Science (PLOS)
- OncoTargets and Therapy
- Pediatric Blood and Cancer
- Clinical Cancer Research
- Journal of the National Comprehensive Cancer Network
- International Journal of Hematology
- Blood Reviews
- Leukemia Research
- Journal of Visualized Experiments
- Biochemical Pharmacology
- Blood Advances
- Cancer
- HemaSphere
- Nature Medicine
- Cancer Discovery
- American Journal of Hematology
- Clinical Lymphoma, Myeloma and Leukemia
- New England Journal of Medicine
- Hematology, the American Society of Hematology Education Program

Invited Lectures and Presentations

Institutional

- Cancer Center Grand Rounds: August 30, 2011
- Developmental Therapeutics Retreat: September 8, 2011
- Department of Medicine's Research and Innovation Series: November 17, 2011
- BMT Morbidity and Mortality Conference: February 28, 2012
- Phase 1 Team Lunch and Learn: June 21, 2012
- Department of Medicine Grand Rounds: March 13, 2013
- Multidisciplinary Leukemia Interest Group: February 7, 2014
- Obstetrics and Gynecology Grand Rounds, "Leukemia in Pregnancy": April 9, 2014
- Bone marrow infusion center breakfast talk, "Clinical Trials in AML/MDS": November 18, 2014
- Department of Medicine Faculty Conference Research in Motion, "Targeting Leukemia Stem Cells in Clinical Trials: New Rules, New Therapies, New Results": February 26, 2015
- 1st Annual University of Colorado Hematologic Malignancies Retreat, "Targeting Leukemia Stem Cells in Clinical Trials: New Rules, New Therapies, New Results": May 14, 2015
- 2nd Annual University of Colorado Hematologic Malignancies Retreat, "mRNA Splicing Genes and Infectious Risk in Myelodysplastic Syndromes": May 2, 2016
- 2nd Annual Colorado Cancer Wellness Conference Panelist. September 17, 2016
- Research Advisory Forum, "Hematology Clinical Trials Unit": October 19, 2016
- Department of Medicine Research and Innovation Conference, "Targeting Leukemia Stem Cells in Clinical Practice: Opportunities and Challenges" January 5, 2017
- University of Colorado Oncology Interest Group Lecture Series Panelist, April 17, 2017
- University of Colorado Pathology Department Grand Rounds, "New Therapies in AML" March 20, 2018
- University of Colorado Department of Medicine Grand Rounds, "Acute Myeloid Leukemia: From a Difficult Past to a Promising Future" August 29, 2018
- Schwartz Center Rounds, University of Colorado, panelist. "Celebrating Success!" December 14, 2018.
- "Adult MDS: Guidelines and New Therapies." Taru Hays Hematology Symposium, University of Colorado Children's Hospital. May 17, 2019.
- "AML in Transition: Targeting Leukemia Stem Cells in the Clinic." Eighth Annual Department of Medicine Research Day. April 6, 2020.
- Cancer Center Mentored Member Workshop: "How to join a translational research/clinical team." September 3, 2020.
- "The Treatment of Elderly Patients with AML." University of Colorado Cancer Center, Cancer and Aging Mini-Symposium. November 2, 2020.
- "Developing Venetoclax for Acute Myeloid Leukemia." University of Colorado Oncology Clinical Research Support Team Education Work Group Lunch and Learn. March 17, 2021.

- “Resistance to Venetoclax in AML”. University of Colorado Cancer Center, Developmental Therapeutics and Investigator Initiated Trials Committees 2021 Mini Retreat. September 9, 2021.
- “Predicting Responses to Venetoclax in AML Patients.” William Hathaway Pediatric Hematology/Oncology/BMT Conference. October 21, 2022.
- “The Cellular Therapies Revolution: Writing the Next Chapter.” University of Colorado Board of Directors Meeting. October 15, 2024.

Regional

- Leukemia and Lymphoma Society Meet the Doctor Series: January 24, 2012, Denver CO
- Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 3, 2013, Denver CO
- Leukemia and Lymphoma Society: Journey of Hope Meeting: April 19, 2013, Denver CO
- Metro Denver Oncology Nursing Society’s Annual Conference: September 26, 2013, Denver CO
- Review of the 2014 American Society of Hematology Annual Meeting: February 6, 2015, Loveland CO
- “Low-intensity Therapeutic Advances in AML”: February 17, 2015, Billings MN via Webinar
- “Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs”: June 8, 2015, Colorado Springs, CO
- “Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs”: October 30, 2015, Poudre Valley Hospital, Ft. Collins, CO
- “Overview of Myeloid Malignancies.” November 14, 2015, University of Colorado, Aurora, CO. Oncology Boot Camp Conference.
- Review of the 2015 American Society of Hematology Annual Meeting: February 6, 2016, Colorado Springs, CO
- Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 16, 2016, Denver CO
- “Acute Myeloid Leukemia.” August 2, 2016, Celgene Medical Affairs Conference, Beaver Creek, CO
- “How Do We Treat MDS?” October 29, 2016, MDS Foundation Educational Patient and Family Forum, Aurora, CO
- “Key Developments and Evolving Strategies for Patients with Myeloproliferative Neoplasms.” October 24, 2016, Santa Fe, New Mexico
- Review of the 2016 American Society of Hematology Annual Meeting: January 27, 2017, Denver CO
- Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 8, 2017, Denver CO
- Acute Myeloid Leukemia MATTERS Summit, Faculty Panelist; May 3, 2017, Denver CO
- Myeloproliferative Neoplasms Panelist, Oncology Nursing Society meeting; May 5, 2017, Denver CO

- Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 7, 2018, Denver CO
- Targeted Oncology Case-Based Peer Perspectives Continuing Medical Education Talk. February 26, 2019, Denver CO
- Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 4, 2019, Denver CO
- Review of the 2019 American Society of Hematology Annual Meeting: February 1, 2020, Denver CO
- “Management of Venetoclax in AML: A Case-Based Approach.” Robert H. Allen MD Memorial Hematology Symposia. July 15, 2021, Denver CO.
- “Promising Clinical Trials and the Future Clinical Landscape of MDS.” MDS Foundation Patient and Family Forum Agenda. September 14, 2024. Denver CO.

National

- “Acute Myeloid Leukemia: Past, Present and Future.” Ohio State University East Grand Rounds, Columbus, OH. September 18, 2009
- “The Utility of Influenza Vaccination for Oncology Patients.” City of Hope Cancer Center, Duarte, CA. October 16, 2012
- Highlights of the Annual American Society of Hematology Meeting: Myelodysplastic Syndrome. Dallas, TX January 17, 2014.
- Highlights of the Annual American Society of Hematology Meeting: Myelodysplastic Syndrome. San Francisco, CA January 24, 2014.
- “Low-Intensity Therapeutic Advances in AML.” Virginia G. Piper Cancer Center Grand Rounds, Scottsdale AZ. October 28, 2014
- “Low-Intensity Therapeutic Advances in AML.” University of Pittsburgh Hillman Cancer Center Grand Rounds, Pittsburgh, PA. February 16, 2015
- “Low-Intensity Therapeutic Advances in AML.” Rush University Grand Rounds, Chicago, IL. March 25, 2015
- “Low-Intensity Therapeutic Advances in AML.” Olive View-UCLA Medical Center Grand Rounds. March 31, 2015.
- “New Therapeutic Advances in Acute Myeloid Leukemia.” Cancer Treatment Centers of America, Annual New Treatments in Oncology Conference (ANTO), Scottsdale, AZ. May 2, 2015.
- “Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs.” Ohio State University East, Columbus, OH. May 7, 2015.
- “Acute Myeloid Leukemia: Applying Emerging Evidence in Practice.” First Annual Twin Cities Hematologic Malignancies Symposium, Minneapolis, MN. October 24, 2015.
- “Targeting Leukemia Stem Cells and Therapeutic Interventions in AML Subpopulations.” BEAT AML Forum, Portland OR. October 27, 2015.
- “Emerging Agents in Myeloid Malignancies.” American Society of Clinical Oncology Oral Abstract Session Discussant, Chicago IL. June 4, 2016.
- “Targeted Therapies for Acute Myeloid Leukemia.” Celgene AML and MDS Workshop, Newark NJ. September 23, 2016.

- “Targeting Leukemia Stem Cells in Clinical Practice: Opportunities and Challenges.” BEAT AML Symposium, Portland OR. October 14, 2016.
- “Assessing Potential Therapeutic Targets in AML.” Highlights of the American Society of Hematology Meeting Satellite Session, Atlanta, GA. January 13, 2017.
- Highlights of the 2016 American Society of Hematology Meeting. Celgene Headquarters, Summit, NJ. February 10, 2017.
- “Acute Myeloid Leukemia Treatment Options.” Webinar, sponsored by Leukemia and Lymphoma Society and the National Marrow Donor Program. May 16, 2017.
- “Venetoclax and Azacitidine in AML: Clinical Experience and Preliminary Correlative Studies.” BEAT AML Forum, Portland, OR. September 12, 2017.
- “BCL-2 Inhibition in AML.” Society of Hematologic Oncology. Houston, TX September 14, 2017.
- “Targeting BCL-2: Venetoclax Combinations and Increasing Off-Label Use.” 4th Annual Think Tank on Integrating New Molecular Targets in acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX January 26-27, 2018.
- “Updates on Myelodysplastic Syndromes.” 2018 Lymphoma Study Group/Hematology Highlights: A Post ASH Review Conference. Omaha, NE February 2-3, 2018.
- “The Herculean Task of Targeting AML Stem Cells.” Emil J. Freireich Leukemia Hematology Grand Rounds, MD Anderson. Houston, TX, February 21, 2018.
- “The Herculean Task of Targeting AML Stem Cells.” The University of Miami March 12, 2018.
- “The Herculean Task of Targeting AML Stem Cells.” Stanford University, March 27, 2018.
- “Which Novel Agents in AML are Likely to Change Practice?” Acute Leukemia Conference, April 13, 2018, Newport Beach, CA.
- Venetoclax in AML: Background Data and Possible Indications. NCCN AML Committee Meeting, May 15, 2018, Philadelphia, PA.
- University of Utah Division of Hematology Symposium and retreat, invited guest speaker. “The Herculean Task of Targeting Leukemia Stem Cells.” Deer Valley Utah, June 8-9 2018
- Leukemia and Lymphoma Society National Board of Directors Meeting Medical and Scientific Affairs Committee Meeting. Special Session on AML. “Targeting AML Stem Cells Through Inhibition of BCL-2: The Current Landscape and Future Directions. Rye Brook NY, June 29, 2018.
- National Comprehensive Cancer Network Congress Series on Acute Leukemia. “Advances in AML Management in Older Patients. Columbus, OH, August 15, 2018.
- American Society of Hematology Educational Session. Acute Myeloid Leukemia: Moving Beyond 7+3. Invited Lecture: New Drugs Inspired by Genomics and When to Use Them. December 1, 2018, San Diego.
- “The Herculean Task of Targeting AML Stem Cells.” The University of Texas Southwestern. February 5, 2019, Dallas.

- “The Herculean Task of Targeting AML Stem Cells.” Research Affinity Group lecture series, Children’s Hospital of Philadelphia Research Institute, University of Pennsylvania. February 25, 2019, Philadelphia.
- “Venetoclax: Current Indications and Emerging Considerations.” National Comprehensive Cancer Network Acute Myeloid Leukemia Committee meeting presentation. May 14, 2019, Philadelphia.
- “All Older Patients and Younger Patients with Adverse Biology Should Receive Venetoclax-Based Therapies Over Standard Intensive Induction Chemotherapy: Debate.” Society of Hematological Oncology annual meeting. September 12, 2019, Houston.
- William Guy Forbeck Research Foundation meeting: Leukemia stem cells, heterogeneity and metabolism- new directions for AML therapy. Speaker and session chair. September 13-15, 2019, Denver.
- “Therapeutic Advances in First-Line AML Management.” National Comprehensive Cancer Network 2019 Annual Congress on Hematologic Malignancies. September 28, 2019, San Francisco, CA
- Research to Practice Year in Review Regional Symposium: Acute Myeloid Leukemia. October 12, 2019, Santa Monica, CA
- “How I Use Venetoclax with Hypomethylating Agents in Newly Diagnosed AML Patients.” Idaho Society of Clinical Oncology annual meeting. November 2, 2019, Boise
- “Venetoclax Combinations in Older Patients.” Oncology Nursing Retreat Annual Meeting. November 8, 2019, Miami
- “Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia.” American Society of Hematology Satellite Symposia. December 6, 2019, Orlando FL.
- “Staying Ahead of the Curve: New Therapeutic Agents in AML.” Continuing medical education event. Seattle WA. January 7, 2020.
- “New Agents and Strategies in the Management of Acute Myeloid Leukemia.” University of Oklahoma Oncology Department Grand Rounds. January 17, 2020.
- “New Agents and Strategies in the Management of Acute Myeloid Leukemia.” Austin, TX. February 4, 2020.
- “Venetoclax in AML.” University of Miami Biennial Leukemia Symposium. February 23, 2020.
- “MDS to AML.” Aplastic Anemia and Myelodysplastic Syndrome International Foundation Annual Meeting. Virtually presented. April 25, 2020.
- “New Agents and Strategies in the Management of Acute Myeloid Leukemia.” Fresno CA, presented virtually, May 22, 2020.
- “The Herculean Task of Targeting AML Stem Cells.” St. Jude Hospital Hematological Malignancies Program. Virtually presented. July 22, 2020.
- “Changing the Treatment Paradigm in AML.” Society of Hematologic Oncology (SOHO) Annual Meeting, Meet the Professor Session. Presented Virtually. September 9, 2020.
- “Staying Ahead of the Curve: New Therapeutic Agents in AML.” Spire Learning CME event. September 30, 2020, presented virtually.

- “Advances in AML Management: Secondary AML and Older Patients with AML.” NCCN Hematologic Malignancies Congress, presented virtually; October 10, 2020.
- “Combination Therapy and Isolation of Effect.” Food and Drug Administration (FDA) internal presentation, for #Project 2025, Drug Development in Acute Myeloid Leukemia. October 28, 2020. Presented virtually.
- “The Herculean Task of Targeting AML Stem Cells.” Memorial Sloan Kettering Cancer Center Grand Rounds. November 3, 2020. Presented virtually.
- Regulatory and Real-World Implications of FDA Oncology Indications. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) Mini-Symposium (Virtual) December 2nd, 2020.
- “Resistance of Venetoclax in Monocytic AML.” Alpine Oncology Foundation Post ASH CML/MPN Workshop (Virtual). December 9-10, 2020.
- “Acute Myeloid Leukemia.” Gilead Medical Scientist Field Team. January 28, 2021 (Presented virtually).
- “Targeting BCL2 in AML.” Third Annual Baylor St. Luke’s Medical Center Hematologic Malignancies symposium. Baylor College of Medicine, Houston
- Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy for AML. Wake Forest Baptist Medical Center Comprehensive Cancer Center (Virtual). May 10, 2021.
- “Advances in Multidisciplinary Management of Acute Myeloid Leukemia.” National Comprehensive Cancer Network Monthly Oncology Tumor Board. Presented virtually. June 17, 2021.
- “Mechanisms of Resistance to IDH Inhibitors” and “Efficacy and Safety of Venetoclax and Azacitidine Combination Therapies in Unfit AML Patients.” AML Expert Forum, Amelia Island, FL. February 11-12, 2022.
- “Promising Clinical Trials in MDS and AML.” 4th Hematologic Malignancies Symposium, Baylor College of Medicine (presented virtually). March 26, 2022.
- American College of Physicians, New York Chapter: Small Feedings of the Soul: Readings and Reflections. Related to “Professional Courtesy” published in Annals of Internal Medicine. June 15, 2022 (virtual).
- “From Plato’s Cave to AML’s New Wave: Optimizing Outcomes with Venetoclax Based Therapies.” Emil Freireich Hematology Grand Rounds, MD Anderson Cancer Center. November 2, 2022 (virtual).
- “Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead.” American Society of Hematology Satellite Symposia. Program Chair. December 9, 2022, New Orleans, LA.
- “Meet the NCCN Guideline Panel Experts: NCCN Academy for Excellence and Leadership in Oncology Roundtable Discussion.” March 31, 2023. Orlando FL.
- “The Future of BCL-2 Inhibition in AML.” University of Miami Biennial Leukemia Symposium. April 1, 2023, Miami FL.
- “Is Acute Myeloid Leukemia with Monocytic Features a Separate Entity?” Society of Hematological Oncology Annual Meeting. September 6, 2023, Houston TX.
- “Found in Translation: Turning Leukemia Stem Cell Discoveries Into Clinical Trials.” Thomas C. Shea Clinical Cancer Symposium. September 18, 2023, Chapel Hill, North Carolina.

- “Comprehensive Molecular Profiling in MDS/AML: The Standard of Care.” The RUNX1 Research Program. November 13, 2023, presented virtually.
- “Unfit AML: Are We Moving on From BCL-2?” 28th Annual International Congress on Hematologic Malignancies. March 1, 2024, Miami, FL.
- “Is It Time to Move On From Venetoclax in Unfit Patients with AML?” 28th Annual Acute Leukemia Forum. April 5, 2024, San Diego.
- “The Development of a Clinical Program Targeting Leukemia Stem Cells: What I Learned from Bev Mitchell and Stanford University.” Tribute to Dr. Bev Mitchell, Stanford Cancer Institute. November 21, 2024, Palo Alto, CA.

International

- “Clinical Predictors of Transplant Related Mortality After Reduced Intensity Allogeneic Stem Cell Transplantation”. *European Hematology Association 10th Congress*, June 2-5, 2005. Stockholm, Sweden (poster presentation)
- “A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” *Targeted Anticancer Therapy Conference*, March 4-6, 2013. Paris, France (poster presentation)
- “Clinical Safety and Activity in a Phase I Trial of AG-120, a First in Class, Selective, Potent Inhibitor of the IDH1-Mutant protein, in Patients with IDH1 Mutant Positive Advanced Hematologic Malignancies.” *EORTC-NCI-AACR Symposium*, November 18-21, 2014. Barcelona, Spain (oral presentation)
- “Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.” European Hematology Association, June 17 2018. Stockholm, Sweden (oral presentation)
- “Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant IDH2 Acute Myeloid Leukemia.” European Hematology Association, June 17, 2018. Stockholm, Sweden (oral presentation)
- “BCL-2 Inhibition to Target AML Stem Cells.” 10th International Heinrich F.C. Behr Symposium on Stem Cells and Cancer, Workshop on Innovative Strategies to Target AML. September 16, 2018. Heidelberg, Germany.
- “Targeting BCL-2 in CLL and AML.” Japanese Society of Hematology 80th Annual Meeting. October 12, 2018. Osaka, Japan.
- “The Herculean Task of Targeting AML Stem Cells.” Japanese Society of Hematology Luncheon Seminar. October 14, 2018. Osaka, Japan.
- “Treatment of AML Without a FLT3 or IDH Mutation.” Spanish Hematology and Hemotherapy Society Global AML Educations Scientific Forum. March 30, 2019. Barcelona, Spain.
- “The Herculean Task of Targeting AML Stem Cells.” University of Toronto Princess Margaret Hospital, Leukemia Academic Grand Rounds. April 1, 2019, Toronto, Canada.
- “The Herculean Task of Targeting AML Stem Cells.” Israeli Society of Hematology and Transfusion Medicine Annual Meeting. September 5, 2019, Kfar Blum, Israel.

- “How I Use Venetoclax with Hypomethylating Agents in Newly Diagnosed AML Patients.” Israeli Society of Hematology and Transfusion Medicine Annual Meeting, Meet the Expert Session. September 5, 2019, Kfar Blum, Israel.
- “Treating AML in 2020: Time for a Paradigm Change.” Rabin Medical Center, Petah Tikvah, Israel. Presented virtually. April 21, 2020.
- The Future of AML: An Evolving Landscape in Patients Ineligible for Intensive Chemotherapy. European Hematology Association Annual Meeting, presented virtually, June 13, 2020.
- “Use of Venetoclax in AML: A Case Based Approach.” Abbvie Brazil (presented virtually), September 23, 2020.
- “Update on BCL-2 Inhibitors.” 9th Annual Acute Leukemia Meeting, MD Anderson Cancer Center, Madrid Spain (presented virtually). September 25, 2020.
- “BCL-2 Inhibition for AML and Beyond.” International MPN-MDS Scientific Conference (presented virtually). November 7, 2020.
- “The Ins and Outs of Venetoclax in Acute Myeloid Leukemia.” Princess Margaret Leukemia Day, October 30, 2020, Toronto, Ontario (presented virtually).
- “BCL-2 as a Stem Cell Target in Acute Myeloid Leukemia.” Japanese Society of Medical Oncology annual meeting, February 18, 2021 (presented virtually)
- “Is Venetoclax + Azacitidine the New Backbone for All AML Combinations?” 4th Annual SINTOMA Meeting, Sao Paulo, Brazil. March 4, 2021 (presented virtually)
- Acute Myeloid Leukemia in a Post-7+3 World.” “Grand Lecture” of the First Annual Paranaense Hematology Conference, Parana, Brazil, March 12, 2021 (presented virtually)
- BCL-2 as a Stem Cell Target in Acute Myeloid Leukemia.” Korean Society of Hematology International Conference, April 1, 2021 (presented virtually)
- Texas (virtual). March 13, 2021.
- “Deepening our Understanding of Venetoclax Based Treatment in Acute Myeloid Leukemia.” AML Awareness Day Meeting, Hematology Department of Sheba Medical Center, Tel Aviv, Israel (presented virtually). April 19, 2021.
- “The Future Role of IDH Inhibitors.” 7th Annual Global Summit on Hematological Malignancies (presented virtually), April 24, 2021.
- “7+3 or Venetoclax + Azacitidine for Complex Karyotype AML.” 3rd International Workshop on Acute Leukaemias (virtual). April 29. 2021.
- “Treating AML in 2021: Time for a Paradigm Change.” The Power of BCL-2 Inhibition: Exploiting Apoptosis in Hematologic Malignancies. Vienna, Austria (virtual). May 6, 2021.
- “The Evolution of AML Treatment in Patients Ineligible for Intensive Chemotherapy.” Hemato-Oncology Program for Experts (HOPE). Saudi Arabia (virtual). June 2, 2021.
- “Current Standard of Care in Treatment Naïve Intensive Chemotherapy Ineligible AML Patients.” Chinese Society of Clinical Oncology International Leukemia and Lymphoma Forum. Shanghai, China (virtual). July 9, 2021.
- “Advances in AML Management: Secondary AML.” 2nd Annual Colloquium on Acute Leukemia and MDS. Mexico (virtual). July 13, 2021.

- “Current Standard of Care in Treatment Naïve Intensive Chemotherapy Ineligible AML Patients.” Argentinian Society of Hematology, Conference on Acute Leukemias and MDS. Rosaria, Argentina (virtual). August 19, 2021.
- “Understanding Resistance to Novel Therapies in AML.” Blood 2021: Annual Australasian Hematology Meeting, Adelaide, Australia (virtual). September 22, 2021.
- “Resistance to Novel Therapies in AML.” Japanese Society of Medical Oncology Annual Meeting. Kyoto, Japan (virtual). February 19, 2022
- “Novel Therapeutic Strategies in AML.” Brazilian Society of Hematology, Hemotherapy and Cell Therapy. March 24, 2022 (virtual)
- “Optimizing Management of Emerging Therapies in AML.” Hematology Society of Taiwan AML and MDS Study Working Group. June 23, 2022 (virtual)
- “Venetoclax Response and Resistance.” 3rd Colloquium of the Coloquio de Leucemias Agudas y Síndrome Mielodisplásico (CLAS). Mexico City, July 20, 2022 (virtual)
- “Navigating New Standards of Care in First Line Unfit AML Patients.” Argentinian Society of Hematology Keynote Address. Buenos Aires, Argentina, August 23, 2022.
- “From Plato’s Cave to AML’s New Wave: Optimizing Outcomes with Venetoclax Based Therapies.” 4th Annual UK NCRI AML Academy, Plenary Lecture. Birmingham, United Kingdom. September 22-23, 2022.
- “From Plato’s Cave to AML’s New Wave: Optimizing Outcomes with Venetoclax Based Therapies.” 17th Chinese Society of Hematology Congress, plenary session, keynote address. September 25, 2022 (presented virtually)
- “How I Treat Newly Diagnosed AML: The Colorado Way.” SAL Study Group AML Symposium. Dresden, Germany. November 18, 2022.
- “Venetoclax in AML: Mechanism and Resistance Factors.” Israeli AML Study Group Meeting, Tel Aviv, Israel. January 30, 2023.
- “Front Line Therapy for Acute Myeloid Leukemia.” Hadassa Medical Center, Jerusalem, Israel. January 30, 2023.
- “Front Line Therapy for Acute Myeloid Leukemia.” Meier Medical Center, Jerusalem, Israel. January 30, 2023.
- “Front Line Therapy for Acute Myeloid Leukemia.” Rambam Medical Center and Other Affiliated Hospitals, Haifa, Israel. February 1, 2023.
- “How I Treat Newly Diagnosed Older AML Patients in 2023.” Brazilian lecture series in Sao Paulo, Salvador, Rio de Janeiro and Curitiba. March, 2023.
- “Found in Translation: Turning Leukemia Stem Cell Discoveries Into Clinical Trials” (*Keynote Lecture*). Nordic AML Group Meeting, Bergen, Norway. August 24-25, 2023.
- “Found in Translation: Turning Leukemia Stem Cell Discoveries Into Clinical Trials.” 11th International Heidelberg Symposium on Stem Cells and Cancer. Heidelberg, Germany. September 10, 2023.
- “Venetoclax with Azacitidine: The Colorado Experience.” European Organisation for Research and Treatment of Cancer (EORTC), Leukemia Group. Annual meeting (presented virtually). October 26, 2023.

- “The Treatment of AML in 2023.” Chinese National Health Association Meeting (webinar, presented virtually). December 15, 2023.
- “Optimizing Management of Emerging Therapies in AML.” Taiwan Society of Blood and Marrow Transplantation (presented virtually). December 16, 2023.
- “Is it Time to Move On From Venetoclax in Unfit Patients with AML?” 5th Coloquio de Leucemias Agudas y Síndrome Mielodisplásico (CLAS). July 1, 2024 (presented virtually).
- “First Line Therapy for AML: Keeping it Simple (But Not Easy!)”. British Hospital, Montevideo, Uruguay. September 30, 2024.
- “Overcoming Venetoclax Resistance in AML.” International Symposium of Acute Leukemias XIX. Munich, Germany. March 18, 2025.

Media Appearances and Interviews

ABC7 News (Denver ABC affiliate). February 6, 2019.

CBS4 News (Denver CBS affiliate). March 11, 2019.

CBS4 News (Denver CBS affiliate). April 7, 2019.

<https://denver.cbslocal.com/video/4061477-cancer-patient-celebrated-at-rockies-game/>

Colorado Matters on Colorado Public Radio. April 5, 2019.

<https://www.cpr.org/news/story/this-cu-drug-trial-may-cure-an-aggressive-strain-of-leukemia-including-this-canon-city>

9News (Denver NBC affiliate). April 8, 2019.

<https://www.9news.com/article/news/local/next/new-drug-trial-at-cu-anschutz-may-be-a-cure-to-a-strain-of-leukemia/73-f85b0afe-5b7c-448c-909f-98a547b69d03>

Fox 31 Denver. September 20, 2019.

<https://kdvr.com/2019/09/18/light-the-night-3/>

Fox Sports National Broadcast, Big Noon College Football program, October 26, 2024

<https://www.foxsports.com/watch/fmc-8tnj9vd6beajdapx>

Teaching Record

- Medical Residency Lecture Series: Leukemia May 29, 2012
- Cancer Research Summer Fellowship lecture, “Acute Myeloid Leukemia: An Overview and Hopeful Future Directions”: July 16, 2015, June 21, 2016, July 18, 2017, July 17, 2018, July 18 2019, June 29 2020, June 24, 2021, 2022, 2023, 2024
- Internal Medicine Residency Program Wednesday Education Sessions “Myeloid Malignancies, Parts 1 and 2”: November 11, 2015 and March 16, 2016
- IDPT 7656: Advanced Foundations of Doctoring, 2015- Current

- Course for MSTP students to maintain and further clinical skills learned during training
- IMMU 7603: The Immunologic Basis of Human Disease, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023
 - Course for immunology program graduate students to provide a mechanistic and clinical understanding of the immunologic basis of human disease
- Internal Medicine Residency panel discussion on academic careers in medicine, October 2, 2018
- BMT Grand Rounds (multiple annual presentations 2011 to present, including AML, CLL, CML, MDS, ALL, MPNs)
- Hematology/Oncology Fellows Conferences (multiple annual presentations from 2011 to present, including AML, ALL, MDS)

Ward and Clinic Attending Duties

- 2011 – Present: Supervision and bedside teaching of medical students, residents, fellows, nurse practitioners and physicians' assistants, 3-4 months/year inpatient (~25 inpatients/day), two half-days a week outpatient (~20 patients/week)

Self-Improvement

- Junior Faculty Mentor Program (JUMP) Workshop, University of Colorado Department of Medicine; focus on developing mentorship skills, Winter/Spring 2016
- Clinical Leadership Development Program, University of Colorado, November/December 2016
- University of Colorado Leadership for Innovative Team Science (LITeS) Program, 2017-2018
- A Competency-Based Approach to Principal Investigator Responsibilities Workshop, University of Colorado, November 6, 2018
- Advocea training course for principal investigators on regulatory requirements for the use of diagnostic tests in clinical studies: CLIA laboratory requirements, FDA investigational device exemption requirements, outcomes of non-compliance. June 15, 2021
- Three-part clinical investigator training course: Regulation and Ethics, Good Clinical Practice and Site Management, July 2021
- Division of Hematology DISC Leadership Styles Training, November 29, 2023

Other Administrative Duties

2015 – 2017: Co-course director (with Jeffrey Schowinsky), myeloid malignancies didactic series for internal medicine residents

2013 – Present: Director of the Leukemia and Myelodysplastic Syndromes Quality Improvement Committees, responsible for publishing internal practice management guidelines for leukemia at the University of Colorado

2019 – 2021: Hematology Clinical Trials Unit Clinical Trials Mentor, responsible for mentorship of all junior clinical faculty doing clinical research and liaison between the HCTU and the faculty

2021 – Present: Medical Director of the HCTU, responsible for operations and faculty engagement in the Hematology Clinical Trials Unit, running all clinical trials for the Division of Hematology

2023 – Present: Associate Chief of Clinical Affairs, Division of Hematology

2024 – Present Interim Chief, Division of Hematology

Mentees

Zohra Nooruddin

2014-2016

Hematology/oncology fellow

Now faculty at San Antonio VA Hospital

Henning Schade

2014-2016

Hematology/oncology fellow

Now in private practice

Biniam Adane

2013-2018

Graduate student, Jordan laboratory

Mentorship committee member

Awarded PhD in 2018

Now working as a researcher in industry

Katherine Minson

2014

Pediatric hematology/oncology fellow

Laboratory of Doug Graham

Scholarship oversight committee member

Now on faculty at Emory University

Kelly Higa

2015-Current

MD/PhD candidate, DeGregori laboratory

Associate mentor, T32 Training Grant

Now a resident in thoracic surgery at Stanford University

Anagha Inguva

2016-Current

MD/PhD candidate

Clinical preceptor

Enkhtsetseg Purev, MD, PhD
2015-2019
Junior Faculty in the Hematology Division, now working in industry

Bradley Haverkos, MD
2015-Current
Junior Faculty in the Hematology Division
Now Associate Professor of Medicine

Peter Forsberg, MD
2016-Current
Junior Faculty in the Hematology Division
Now Associate Professor of Medicine

Courtney Jones, PhD
2016-Current
Postdoctoral Fellow, now on faculty at the University of Toronto
Career Development Committee

James Dugan, MD
2016-2019
Hematology/Oncology fellow
Now in private practice

Hae J Park
2018-Current
MD/PhD candidate
Thesis committee member

Brett Stevens, PhD
Assistant Professor
Research Faculty
Now Research Associate Professor

Shanshan Pei, PhD
Assistant Professor
Research Faculty

Mohd Minhajuddin, PhD
Assistant Professor
Research Faculty

Marc Schwartz, MD
Assistant Professor
Hematology Division

Christine McMahon, MD
Assistant Professor
Hematology Division

Lindsey Murphy, MD
Pediatric Hematology/Oncology Fellow

Zach Graff, MD
Pediatric Hematology/Oncology Fellow
Now on faculty at the Medical College of Wisconsin

Natalia Gurule, PhD
Post Doctoral Research Fellow
Alper laboratory, National Jewish Health
T32 committee

Sweta Patel, PhD
Post Doctoral Research Fellow
Jordan/Pietras Lab
Committee Member

Ana Vujovic, PhD
Post Doctoral Research Fellow
Jordan Lab
Committee Member

Andrew Kent, MD, PhD
Clinical Fellow, Division of Hematology
Now Assistant Professor in Division of Hematology

Jacob Fang
Medical Student
Now radiology resident at University of Chicago

Jason Gilbert, MD
Internal Medicine Resident
Now hospitalist attending at University of Colorado

Mat Angelos, MD, PhD
Assistant Professor, Division of Hematology

Ian Shelton
Graduate Student, Jordan Laboratory
Thesis Committee Member

Tori Knox-Rice, PhD

Psychologist
Assistant Professor, Division of Hematologist

Grant Support

Active

Specialized Center of Research (SCOR) 09/01/18-8/31/25 2.0 cal
Leukemia and Lymphoma Society \$1,000,000/yr
Therapeutic Targeting of AML Stem Cells
Role: Co-leader of Project #4
Goal: To develop multi-modal personalized therapeutic strategies designed to eradicate AML stem cells

1R01AI155749 (Alper) 03/11/21 – 02/28/26 0.6 cal
NIAID
MDS-associated spliceosome mutations regulate host defense
Role: Co-Investigator
Goal: To study the impact of RNA splice gene mutations on immune function

Academic Clinical Trials Program 07/01/24-06/30/27
Leukemia and Lymphoma Society \$1,000,000
Lower Dose Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Role: PI
Goal: To support the clinical trial investigating lower dose mitoxantrone to overcome venetoclax resistance

R01 CA292432-01 07/01/2024 – 06/30/2029
NIH/NCI
IAP Inhibition as a Therapeutic Strategy to Target Therapy-Resistant Leukemia Initiating Cells
Role: Co-PI (with DeGregori)
Goal: The goal is to identify and target the specific vulnerabilities of distinct therapy-resistant subpopulations within AML

1R01CA292071-01 07/01/2024 – 06/30/2029
NIH/NCI
Targeting mitochondrial calcium to eradicate leukemia-initiating cells
Role: Co-PI (with Jordan)
Goals: The goal is to explore the impact of mitochondrial calcium fluctuations as a functional target for leukemia stem cells

Equity in Access Research Grant 07/01/2024 – 06/30/2025
Leukemia and Lymphoma Society
The Impossible Choice: The Role of Insurance Design on Financial Toxicity and Access to Care for Individuals with Blood Cancer

Role: Investigator (PI: Parsons)

Goals: Understand the role of insurance design on financial toxicity and access to care among individuals with blood cancer

Completed

PI: Daniel A. Pollyea
Title: Targeting Leukemia Stem Cells in the Clinical Setting: The Development of A Comprehensive Program
Agency: Leukemia and Lymphoma Society
Period: 07/01/19 – 06/30/24
Award: \$625,000

PI: Daniel A. Pollyea
Title: Targeting Myeloid Malignancy Stem Cells Through the Pursuit of Novel Clinical Trials
Agency: V Foundation
Period: 11/1/21 to 10/31/23
Award: \$200,000

PI: Daniel A. Pollyea
Title: A clinical and translational developmental therapeutics program focused on targeting leukemia stem cells
Agency: University of Colorado Department of Medicine Outstanding Early Career Scholars Program
Period: 7/1/15-6/30/20
Award: \$375,000 (total direct costs)

PI: Daniel A. Pollyea
Title: Targeting the hedgehog signaling pathway in post allogeneic stem cell transplant patients
Agency: Leukemia and Lymphoma Society Therapy Acceleration Program
Period: 7/1/13-6/30/16
Award: \$354,000 (total direct costs)

Co-PI: Daniel A. Pollyea
Title: Characterization and targeting of MDS stem cells
Agency: Edward P. Evans Foundation, MDS Basic Science Research Grant
Period: 7/1/15-6/30/17
Award: \$400,000 (total direct costs)

Co-I: Daniel A. Pollyea
Title: Targeting unique metabolic dependencies to eradicate leukemia stem cells
Agency: Leukemia and Lymphoma Society Therapy Acceleration Program
Agency: University of Colorado Department of Medicine Team Science Award

Period: 2016
Award: \$40,000

PI: Daniel A. Pollyea
Title: Targeting cancer stem cells through inhibition of Bcl-2 in acute myeloid leukemia and myelodysplastic syndrome
Agency: NIH Loan Repayment Program
Period: 7/1/10-6/30/17

Agency: NIH KL2 Mentored Career Development Award
Period: 7/1/09-6/30/11

PI: Daniel A. Pollyea
Agency: American Society of Clinical Oncology Young Investigator Award
Period: 7/1/09-6/30/10
Award: \$50,000

PI: Daniel A. Pollyea
Agency: American Society of Hematology Research Training Award for Fellows
Period: 7/1/09-6/30/10
Award: \$50,000

PI: Daniel A. Pollyea
Agency: Leukemia and Lymphoma Society Special Fellow in Clinical Research Career Development Award
Period: 7/1/10-6/30/13
Award: \$195,000

PI: Daniel A. Pollyea
Agency: Cancer League of Colorado Pilot Grant: Ibrutinib with lenalidomide for chronic lymphocytic leukemia
Period: 7/1/13-6/30/15
Award: \$30,000

PI: Daniel A. Pollyea
Title: Lenalidomide in leukemia clinical trials
Agency: American Society of Clinical Oncology Career Development Award
Period: 7/1/13-6/30/16
Award: \$200,000

Co-PI: Daniel A. Pollyea
Title: mRNA splicing, innate immunity and the pathogenesis of MDS
Agency: Cancer League of Colorado Pilot Grant
Period: 7/1/15-6/30/16
Award: \$30,000

Co-PI: Daniel A. Pollyea
Title: Splicing gene mutations and infection in MDS patients
Agency: Cancer League of Colorado Pilot Grant
Period: 7/1/16-6/30/17
Award: \$30,000

Not Awarded

Co-PI	Targeting cancer stem cells through inhibition of Bcl-2 in acute myeloid leukemia	R01CA197524	
PI	Novel therapeutic combinations with lenalidomide for relapsed and refractory leukemia	K23CA177873	
Co-PI	mRNA splicing and the pathogenesis of hematological malignancies	R21 NCI CA195160	Impact score 25, 10 th percentile (7-17-15)
Co-PI	Characterization of MDS stem cells and development of novel therapeutics	R21 NCI CA198445	Impact score 25, 10 th percentile (12-9-15)
PI	Targeting the Metabolism of MDS Stem Cells	Leukemia and Lymphoma Society Translational Research Program	

Bibliography

Peer-Reviewed Manuscripts

1. Huang J, Frischer JS, New T, Kim EG, Serur A, Lee A, Kadenhe-Chiwishe A, **Pollyea DA**, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. TNP-470 promotes initial vascular sprouting in xenograft tumors. *Molecular Cancer Therapeutics*, 2004;3(3):335-343.
2. Kline J, **Pollyea DA**, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant Ganciclovir and post-transplant high-dose valacyclovir reduce CMV infections after alemtuzumab based conditioning. *Bone Marrow Transplant* 2006;3:307-10.
3. Artz A, **Pollyea D**, Kocherginsky M, Daugherty C, Zimmerman T, Smith S, Godley L, Thirman M, Rich E, Larson R, Stock W, Balducci L, Van Besien K. Performance status and comorbidity determine transplant related mortality after allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplant*. 2006 Sep;12(9):954-64.

4. Michaelis L, Lin S, Joseph L, Artz AS, Kline J, **Pollyea D**, Stock W, Rich E, Collins-Jones D, Casey B, Cerro PD, van Besien K. Chimerism does not predict for outcome after alemtuzumab based conditioning. *Bone Marrow Transplant*. 2007 Jul;40(2):181.
5. **Pollyea DA**, Artz A, Stock W, Daugherty C, Godley L, Odenike O, Rich E, Smith S, Zimmerman T, Zhang Y, Huo D, Larson R, Van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2007 Dec;40(11):1027-32.
6. **Pollyea DA**, George TI, Corless C, Gotlib J. When yellow jackets attack: Recurrent and severe anaphylactic reactions to insect bites and stings. *American Journal of Hematology*. 2009 Dec;84(12):843-6.
7. **Pollyea DA**, Brown J, Horning SJ. The utility of influenza vaccination for oncology patients. *Journal of Clinical Oncology*. 2010 May 10;28(14):2481-90.
8. Kohrt H, Patel P, Ho M, Owen T, **Pollyea D**, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh A, and Medeiros B. Second line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. *American Journal of Hematology*. 2010 Nov;85(11):877-81.
9. Huang M, Whang P, Chodaparambil JV, **Pollyea DA**, Kusler B, Xu L, Felsher DW, Mitchell BS. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. *Journal of Biological Chemistry*. 2011 Apr 1;286(13):11035-46.
10. **Pollyea DA**, Kohrt HE, Medeiros BC. Acute Myeloid Leukemia in the Elderly: A Review. *British Journal of Haematology*. 2011 Mar; 152(5):524-42.
11. **Pollyea DA**, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. *Hematological Oncology*. 2011 Sep;29(3):157-60.
12. **Pollyea DA**, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC. Safety, Efficacy and Biological Predictors of Response to Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia. *Leukemia*. 2012 May;26(5):893-901.
13. **Pollyea DA**, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BC. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient

responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. *Leuk Lymphoma*. 2013 Feb;54(2):408-10.

14. **Pollyea DA**, Zehnder J, Coutre S, Gotlib J, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS, Medeiros BC. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. *Haematologica*. 2013 Apr;98(4):591-6.
15. Coffey DG, **Pollyea DA**, Myint H, Smith C, Gutman JA. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. *Bone Marrow Transplant*. 2013 Sep;48(9):1253-6.
16. Narayanan V, **Pollyea DA**, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. *Drugs Today (Barc)*. 2013 Apr;49(4):261-9.
17. Maxson JE, Gotlib J, **Pollyea DA**, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. *New England Journal of Medicine*. 2013 May 9;368(19):1781-90.
18. Narayanan V, Gutman JA, **Pollyea DA**, Jimeno A. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. *Drugs Today*. 2013 Jul;49(7):447-56.
19. Ravandi F, Erba HP, **Pollyea DA**. Expert insights into the contemporary management of older adults with acute myeloid leukemia. *Cancer Control*. 2013 Oct;20(4 Suppl):5-16.
20. Smith C, Gasparetto M, Humphries K, **Pollyea DA**, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. *Ann N Y Acad Sci*. 2014 Mar;1310(1):58-68.
21. Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, **Pollyea DA**, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1+ leukemia. *American Journal of Hematology*. 2014 Sep;89(9):896-903.
22. **Pollyea DA**, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. *Haematologica*. 2014 Aug;99(8):1277-1284.
23. **Pollyea DA**, Gutman JA. Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. *Curr Hematol Malig Rep*. 2014 Dec;9(4):421-31.

24. Smith C, Gasparetto M, Jordan C, **Pollyea DA**, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. *Adv Exp Med Biol*. 2015;815:349-59.
25. Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, **Pollyea DA**, Jordan CT, Serkova NJ, Graham DK, DeGregori J. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. *Clinical Cancer Research*. 2015 Mar 15;21(6):1360-72.
26. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, **Pollyea DA**, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shad DA, Smith C. Myelodysplastic syndromes, version 2.2015. *Journal of the National Comprehensive Cancer Network*. 2015 Mar;13(3):261-72.
27. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, **Pollyea DA**, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. *Journal of the National Comprehensive Cancer Network*. 2015 Apr;13(4):424-34.
28. Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, Sauntharajah Y, Du Y, Oakley K, Nguyen N, Mukherjee S, Pabst C, Godley LA, Churpek JE, **Pollyea DA**, Krug U, Berdel WE, Klein HU, Dugas M, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Ogawa S, Müller-Tidow C, Maciejewski JP. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. *Cancer Cell*. 2015 May 11;27(5):658-70.
29. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, **Pollyea DA**, Jordan CT, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. *Cell Research*. 2015 Jun;25(6):707-25.
30. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee C, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee H, **Pollyea DA**. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. *Leukemia and Lymphoma*. 2016 Apr;57(4):927-34.

31. Smith KS, Yadav VK, Pei S, **Pollyea DA**, Jordan CT, De S. SomVarIUS: Somatic variant identification from unpaired tissue samples. *Bioinformatics*. 2016 Mar 15;32(6):808-13. PMID:26589277
32. Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, Schreiber AW, Feng J, Babic M, Chong CE, Lee Y, Yong A, Suthers GK, Poplawski N, Altree M, Phillips K, Jaensch L, Fine M, D'Andrea RJ, Lewis ID, Medeiros BC, **Pollyea DA**, King MC, Walsh T, Keel S, Shimamura A, Godley LA, Hahn CN, Churpek JN, Scott HS. Novel germline DDX41 mutations define families with a lower age of MDS/AML onset, and lymphoid malignancies. *Blood*. 2016 Feb 25;127(8):1017-23. PMID:26712909
33. Riedel SS, Haladyna JN, Bezzant M, Stevens B, **Pollyea DA**, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. *J Clin Invest*. 2016 Apr 1;126(4):1438-50. PMID: 26927674
34. Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, **Pollyea DA**. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. *Bone Marrow Transplant*. 2016 Jul 11. Epub ahead of print. PMID: 27400068
35. Konopleva M, **Pollyea DA**, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Levenson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. *Cancer Discov*. 2016 Aug 12. Epub ahead of print. PMID: 27520294
36. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, **Pollyea DA**, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Segrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. *BMC Cancer*. 2016 Aug 19;16:652. E pub ahead of print. PMID: 27538433
37. Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, **Pollyea DA**, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. *J Biol Chem*. 2016 Aug 29. Epub ahead of print. PMID: 27573247

38. Medeiros BC, Fathi AT, DiNardo CD, **Pollyea DA**, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. *Leukemia*. 2016 Oct 10. PMID:27721426
39. Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, **Pollyea DA**, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 2016 Oct 25;113(43):E6669-E6678. PMID: 27791036
40. Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, **Pollyea DA**, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016 Dec;14(12):1572-1611. PMID:27956542
41. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, **Pollyea DA**, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017 Jan;15(1):60-87. PMID:28040720
42. **Pollyea DA**, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. *Blood*. 2017 Feb 3. doi: 10.1182/blood-2016-10-696039. [Epub ahead of print] PMID:28159738
43. Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, Purev E, Gutman JA, Robinson W, **Pollyea DA**. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. *Haematologica*. 2017 Feb 16. doi: 10.3324/haematol.2016.163089. [Epub ahead of print] PMID: 28209656
44. Gasparetto M, Pei S, Minhajuddin M, Khan N, **Pollyea DA**, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. *Haematologica*. 2017 Mar 9. [Epub ahead of print] PMID: 28280079
45. Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, **Pollyea DA**, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression

in Acute Myeloid Leukemia. *Cell Rep*. 2017 Mar 28;18(13):3204-3218.
PMID:28355571

46. Stein EM, DiNardo CD, **Pollyea DA**, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn WI, Kantarjian H, Collins R, Patel MR, Franel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. *Blood*. 2017 Jun 6. Epub ahead of print. PMID: 28588020.
47. Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, **Pollyea DA**, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. *New England Journal of Medicine*. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767. PMID:28679093
48. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, **Pollyea DA**, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116. PMID:28687581
49. Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, Enlight I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, **Pollyea DA**, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies. *Proc Natl Acad Sci USA*. 2017 Aug 7. doi: 10.1073/pnas.1703094114. PMID: 1703094114 [Epub ahead of print]
50. Stansfield LC, **Pollyea DA**. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. *Pharmacotherapy*. 2017 Oct 4. doi: 10.1002/phar.2039. [Epub ahead of print] PMID: 28976600
51. Medeiros BC, McCaul K, Kambhampati S, **Pollyea DA**, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons ≥ 65 years with newly-diagnosed acute myeloid leukemia. *Haematologica*. 2017 Nov 2. pii: haematol.2017.172353. doi: 10.3324/haematol.2017.172353. [Epub ahead of print] PMID: 29097499

52. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, **Pollyea DA**. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukemia: a non-randomized, open label, phase 1b study. *Lancet Oncology*. 2018 Feb;19(2):216-228. Epub 2018 Jan 12. PMID: 29339097.
53. Savona MR, **Pollyea DA**, Stock W, Oehler VG, Schroeder MA, Lancet JE, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Larid AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase 1b study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. *Clin Cancer Res*. 2018 Feb 20. Epub ahead of print. PMID: 29463550
54. **Pollyea DA**, Hedin BR, O'Connor BP, Alper S. Monocyte function in patients with myelodysplastic syndrome. *J Leukoc Biol*. 2018 Apr 14. doi:10.1002/JLB.5AB1017-419RR. Epub ahead of print. PMID: 29656609
55. Sharma P, **Pollyea DA**, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa based intensified reduced intensity conditioning adult double-unit cord blood hematopoietic stem cell transplantation results in decreased relapsed rate and improved survival compared to transplantation following standard reduced intensity conditioning: a retrospective cohort comparison. *Biol Blood Marrow Transplant*. 2018 Apr 20. pii: S1083-8791(18)30200-3. doi: 10.1016/j.bbmt.2018.04.019. [Epub ahead of print] PMID:29684565
56. Amaya ML, **Pollyea DA**. Targeting the IDH2 Pathway in Acute Myeloid Leukemia. *Clin Cancer Res*. 2018 May 16. pii: clincanres.0536.2018. doi: 10.1158/1078-0432.CCR-18-0536. [Epub ahead of print] PMID:29769206
57. Dugan J, **Pollyea DA**. Enasidenib for the treatment of acute myeloid leukemia. *Expert Rev Clin Pharmacol*. 2018 May 17. doi:10.1080/17512433.2018.1477585. [Epub ahead of print] PMID:29770715
58. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, **Pollyea DA**, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. *New England Journal of Medicine*. 2018 Jun 2. doi: 10.1056/NEJMoa1716984. [Epub ahead of print] PMID: 29860938

59. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, **Pollyea DA**, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy is Required for Self-Renewal of Human AML Stem Cells. *Cell Stem Cell*. 2018 Jun 6. pii: S1934-5909(18)30239-X. doi: 10.1016/j.stem.2018.05.021. [Epub ahead of print] PMID: 29910151
60. Sharma P, **Pollyea DA**. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. *Curr Hematol Malig Rep*. 2018 Jul 7. doi: 10.1007/s11899-018-0464-8. [Epub ahead of print] PMID:29982865
61. **Pollyea DA**. Next-Generation Sequencing and Eating of the Tree of Knowledge. *Clin Cancer Res*. 2018 Jul 23. pii: clincanres.1835.2018. doi: 10.1158/1078-0432.CCR-18-1835. [Epub ahead of print] PMID:30037820
62. Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, **Pollyea DA**, Sekeres MA, Robak T, Ma WW, Zeremski M, Shaik MN, Laird AD, O'Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. *Am J Hematol*. 2018 Aug 3. doi: 10.1002/ajh.25238. [Epub ahead of print] PMID:30074259
63. Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, **Pollyea DA**, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. *Nat Commun*. 2018 Sept 12;9(1):3694. PMID: 30209285.
64. Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, **Pollyea DA**, Lozupone CA, Serkova NJ, Colgan SP, Jordan CT. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. *Cancer Cell*. 2018 Oct 8;34(4):659-673. PMID: 30270124.
65. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, **Pollyea DA**, Swords RT, Watts JM, Weir SJ, Wiest DL,

- Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. *Nature*. 2018 Oct;562(7728):526-531. PMID:30333627.
66. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, We AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, **Pollyea DA**, Letai A. Venetodax combined with decitabine or azactidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood*. 2018 Oct 25, Epub ahead of print, PMID: 30361262.
67. **Pollyea DA**, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselbert JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in acute myeloid leukemia patients. *Nat Med*. 2018 Nov 12. doi: 10.1038/s41591-018-0233-1. [Epub ahead of print] PMID: 30420752
68. Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Reinhold D, Smith C, DeGregori J, **Pollyea DA**, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. *Cancer Cell*. 2018 Nov 12;34(5):724-740.e4. doi: 10.1016/j.ccell.2018.10.005. PMID:30423294
69. **Pollyea DA**. Which novel agents for acute myeloid leukemia are likely to change practice? *Best Pract Res Clin Haematol*. 2018 Dec;31(4):391-395. Epub 2018 Sep 20. Review. PMID:30466754
70. Stein EM, DiNardo CD, Fathi AT, **Pollyea DA**, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular remission and response patterns in patients with mutant-*IDH2* acute myeloid leukemia treated with enasidenib. *Blood*. 2018 Dec 3. [Epub ahead of print] PMID: 30510081
71. **Pollyea DA**. New drugs for acute myeloid leukemia inspired by genomics and when to use them. *Hematology Am Soc Hematol Educ Program*. 2018 Nov 30;2018(1):45-50. PMID: 30504290
72. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, **Pollyea DA**, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*. 2018 Dec 16. [Epub ahead of print] PMID: 30555165

73. **Pollyea DA**, Jordan CT. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? *Curr Opin Hematol*. 2019 Mar;26(2):71-76. PMID:30652974
74. **Pollyea DA**, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. *Haematologica*. 2019 Mar 7. [Epub ahead of print] PMID:30846499
75. Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, **Pollyea DA**, Becker MW, Jordan CT. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. *Cell Rep*. 2019 Apr 2;27(1):238-254.e6. PMID:30943405
76. Medeiros BC, Chan SM, Daver NG, Jonas BA, **Pollyea DA**. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. *Am J Hematol*. 2019 Apr 3. doi: 10.1002/ajh.25484. [Epub ahead of print] PMID:30945331
77. **Pollyea DA**, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. *Leukemia*. 2019 Apr 9. [Epub ahead of print] PMID: 30967620
78. Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, **Pollyea DA**. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. *Leukemia Research*. 2019 Apr 13;81:43-49 [Epub ahead of print] PMID:31009835.
79. Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, **Pollyea DA**, Jordan CT. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. *Blood*. 2019 May 17. [Epub ahead of print] PMID: 31101624
80. Stevens BM, Zhang W, **Pollyea DA**, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T cells for the treatment of myelodysplastic syndrome. *Exp Hematol*. 2019 May 25. pii: S0301-472X(19)30319-4. doi: 10.1016/j.exphem.2019.05.002. [Epub ahead of print] PMID:31136781

81. **Pollyea DA.** Acute myeloid leukemia drug development in the post-venetoclax era. *Am J Hematol.* 2019 Jun 9. doi: 10.1002/ajh.25556. [Epub ahead of print] PMID:31179583
82. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, **Pollyea DA**, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028. PMID:31200351
83. Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, **Pollyea DA**, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. *Blood.* 2019 Sep 12;134(11):867-879. Epub 2019 Jul 31. PMID: 31366621
84. Jonas BA, **Pollyea DA.** How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. *Leukemia.* 2019 Oct 18. Epub ahead of print. PMID: 31628431
85. Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, **Pollyea DA.** Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. *Blood Adv.* 2019 Oct 22;3(20):2911-2919. PMID: 31648312
86. **Pollyea DA.** Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia. *J Natl Compr Canc Netw.* 2019 Nov;17(11.5):1441-43. PMID: 31766013.
87. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, **Pollyea DA**, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. *Blood.* 2019 Dec 16. PMID:31841594

88. Stein EM, DiNardo CD, **Pollyea DA**, Schuh AC. Response Kinetics and Clinical Benefits of Non intensive AML Therapies in the Absence of Morphologic Response. *Clin Lymphoma Myeloma Leuk*. 2019 Nov 26. PMID:31862181
89. **Pollyea DA**, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: Changing the treatment paradigm. *Blood Adv*. 2019 Dec 23;3(24):4326-4335. PMID:31869416
90. Gutman JA and **Pollyea DA**. Hypomethylating agents with venetoclax: have we discovered the holy grail? *Curr Opin Hematol*. 2020;27(2):76–80.
91. Pei S, **Pollyea DA**, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costeollo JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan Ct. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. *Cancer Discov*. 2020 Apr;10(4):536-551. PMID: 31974170.
92. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnelan W, Erba HP, Mannis GN, **Pollyea DA**, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Ettar EC, Stone RM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. *Blood*. 2020;135(7):463-471. doi:10.1182/blood.2019002140
93. Stein EM, Fathi AT, DiNardo CD, **Pollyea DA**, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarkian HM. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. *Lancet Haematol*. 2020;7(4):e309-e319. doi:10.1016/S2352-3026(19)30284-4
94. Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, **Pollyea DA**, Ossenkoppele G, Giralto S, Dohner H, Heuser M, Siu L, Singh I, Huang F, Larsen JS, Wei AH. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study [published online ahead of print, 2020 Mar 16]. *Leukemia*. 2020;10.1038/s41375-020-0773-5. doi:10.1038/s41375-020-0773-5
95. Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Watts JM, **Pollyea DA**, Fathi AT, Tallman MS, Kantarjian HM, Stone

- RM, Quek L, Konteatis Z, Dang L, Ncolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Ettar EC, Wu B. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. *Blood Adv.* 2020;4(9):1894-1905. doi:10.1182/bloodadvances.2020001503
96. Sharma P, Purev E, Haverkos B, **Pollyea DA**, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. *Blood Adv.* 2020;4(10):2227-2235. doi:10.1182/bloodadvances.2020001554
97. Bock AM, **Pollyea DA**. Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia. *Am J Hematol.* 2020;10.1002/ajh.25916. doi:10.1002/ajh.25916
98. Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, **Pollyea DA**. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeic stem cell transplant relapse. *Blood Adv.* 2020;4(13):3102-3108.
99. Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, **Pollyea DA**, Ferdinand R, Ma WW, O'Brian T, O'Connell A, Chan G, Heuser M. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. *J Hematol Oncol.* 2020;13(1):92.
100. Jones CL, Stevens BM, **Pollyea DA**, Culp-Hill R, Reisz JA, Nemkov T, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajudiin M, Abbott D, Becker MW, Deregori J, Smith CA, D'Alessandro A, Jordan CT. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. *Cell Stem Cell.* 2020 Nov 5;27(5):748-64. PMID: 32822582.
101. **Pollyea DA**. Venetoclax in AML: Where We Are and Where We Are Headed. *Clin Lymphoma Myeloma Leuk.* 2020;20 Suppl 1:S25-S26. doi:10.1016/S2152-2650(20)30450-X.
102. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, **Pollyea DA**, McCloskey J, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. *Blood.* 2020 Sep 5. PMID: 33024987

103. Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, **Pollyea DA**, Christians U, Grimes HL, D'Alessandro A, Jordan CT. The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG. *Cancer Discov.* 2020 Oct 7:CD-20-0318. PMID: 33028621
104. **Pollyea DA**, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. *Am J Hematol.* 2020 Oct 29. PMID: 33119898
105. Daver N, Wei AH, **Pollyea DA**, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. *Blood Cancer J.* 2020 Oct 30;10(10):107. PMID: 33127875
106. **Pollyea DA**, Kim HM, Stevens BM, Lee FF, Harris C, Hedin BR, Knapp JR, O'Connor BP, Jordan CT, Pietras EM, Tan AC, Alper S. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. *J Leukoc Biol.* 2020 Nov 6. PMID: 33155727
107. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, **Pollyea DA**, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. *Int J Lab Hematol.* 2020 Nov 21. PMID: 33220019
108. Shallis RM, **Pollyea DA**, Zeidan. Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials. *Lancet Haematol.* 2020 Dec;7(12):853-856. PMID: 33242436
109. Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, **Pollyea DA**. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. *Leuk Lymphoma.* 2020 Dec 30:1-9. PMID: 33375853
110. **Pollyea DA**, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. *J Natl Compr Canc Netw.* 2021 Jan 6;19(1):16-27. PMID: 33406488

111. Shallis RM, **Pollyea DA**, Zeidan AM. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. *Blood Rev.* 2021 Jan 29. PMID: 33531169
112. Daver N, Salhotra A, Brandwein JM, Podoltsev NA, **Pollyea DA**, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. *Am J Hematol.* 2021 Feb 22. PMID: 33617672
113. Stevens BM, Jones CL, **Pollyea DA**, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, Jordan CT. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. *Nat Cancer.* 2020 Dec;1(12):1176-1187. PMID: 33884374
114. Short NJ, Tallman MS, **Pollyea DA**, Ravandi F, Kantarjian H. Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. *J Clin Oncol.* 2021 May 27. PMID: 34043455
115. Inguva A, **Pollyea DA**. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML. *Clin Lymphoma Myeloma Leuk.* 2021 Jul 18: S2152-2650(21). PMID: 34389272
116. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, **Pollyea DA**, Radhakrishnan SM, Radhakrishnan S, Patel PA, Collins RH, Tantravahi SK, Deininger MW, Fan G, Druker BJ, Shinde U, Tyner JW, Press RD, McWeeney SK, Agarwal A. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. *Blood.* 2021 Sep 5. PMID: 34482403
117. Amaya M, Inguva A, Pei S, Jones CL, Krug A, Ye H, Minhajuddin M, Winters AC, Furtek SL, Gamboni F, Stevens BM, D'Alessandro A, **Pollyea DA**, Reigan P, Jordan CT. The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation. *Blood.* 2021 Sep 15. PMID: 34525179
118. Cherry E, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky JT, Inguva A, Minhajuddin M, Pei S, Stevens BM, Winters AC, Jordan CT, Smith C, Gutman JA, **Pollyea DA**. Venetoclax and azacitidine compared to induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. *Blood Adv.* 2021 Oct 5: PMID: 34610123
119. **Pollyea DA**, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by

allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. *Bone Marrow Transplant*. 2021 Oct 13. PMID: 34645926

120. Inguva A, **Pollyea DA**. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML. *Clin Lymphoma Myeloma Leuk*. 2021 Dec;21(12):805-811. 2021 Jul 18. PMID: 34389272
121. Gerds AT, Scott BL, Greenberg PL, Lin TL, **Pollyea DA**, Verma AK, Dail M, Feng Y, Green C, Ma C, Medeiros BC, Yan M, Yousefi K, Donnellan WB. Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. *Blood Adv*. 2021 Dec 21. PMID: 34932793.
122. DiNardo CD, **Pollyea DA**. Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. *J Clin Oncol*. 2022 Jan 10: PMID: 35007124.
123. **Pollyea DA**, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and *IDH1/2* mutations. *Clin Cancer Res*. 2022 Jan 19: PMID: 35046058
124. Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, **Pollyea DA**, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. *Blood*. 2022 Jan 27;139(4):584-596. PMID: 34525179
125. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Gognon C, Bock AM, **Pollyea DA**, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. *Blood*. 2022 Feb 24;139(8):120801221. PMID:34482403
126. **Pollyea DA**, Barrett J, DiNardo CD, Michaelis LC, Roboz GJ, Le RQ, Norsworthy KJ, de Claro RA, Theoret MR, Pazdur R. Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. *Clin Cancer Res*. 2022 Mar 1;28(5):816-820. PMID: 34753779
127. Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, **Pollyea D**, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective Pivotal translational hematology and therapeutic insights in chronic

- myeloid hematopoietic stem cell malignancies. *Hematol Oncol*. 2022 Apr 3. PMID: 35368098
128. **Pollyea, DA**. Professional Courtesy. *Ann Intern Med*. April 26, 2022. PMID: 35467936
 129. Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, **Pollyea DA**, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. *Blood Adv*. 2022 May 5. PMID: 35511730
 130. Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblenz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Montebianco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A, Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, Jordan CT, Lin TL, Martinez ME, Pallapati RR, **Pollyea DA**, Pomicter AD, Watts JM, Weir SJ, Druker BJ, McWeeney SK, Tyner JW. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. *Cancer Cell*. 2022 July 20:S1535-6108(22)00312-9. PMID: 35868306.
 131. Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, **Pollyea DA**, Gutman JA. Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. *Transplant Cell Ther*. 2022 Jul 25:S2666-6367(22)01509-3. PMID: 35902048
 132. **Pollyea DA**, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. *Clin Cancer Res*. 2022 Aug 25. PMID: 36007102.
 133. Zhang A, Johnson T, Abbott D, Phupitakphol T, Gutman JA, **Pollyea DA**, Koullias Y. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine. *Open Forum Infect Dis*. 2022 Sep 24;9(10). PMID: 36225746.
 134. Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, **Pollyea DA**, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Venetoclax and idasanutlin in

- relapsed/refractory AML: a non-randomized, open-label phase 1b trial. *Blood*. 2022 Oct 20. PMID: 36265087.
135. Zeidan AM, Borate U, **Pollyea DA**, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. *Am J Hematol*. 2022 Oct 30. PMID: 36309981
 136. Ahmed M, **Pollyea DA**. Lower intensity regimens for acute myeloid leukemia: opportunities and challenges. *Leuk Lymphoma*. 2022 Nov 2:1-5. PMID: 36323295
 137. Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, **Pollyea DA**, Davies FE, Morgan GJ, Glass J, Kamdar M, Mateos Manteca MV, Tovar N, Yeh P, García Delgado R, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. *Clin Cancer Res*. 2022 Nov 9. PMID: 36350312
 138. Carraway HE, **Pollyea DA**, Stein EM. Recent progress in acute leukemia and myelodysplasia. *Best Pract Res Clin Haematol*. 2022 Dec;35(4):101415. PMID: 36517125
 139. Kent A, **Pollyea DA**. Top advances of the year: Leukemia. *Cancer*. 2022 Dec 30. PMID: 36585394
 140. Zeidan AM, **Pollyea DA**, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. *Ann Hematol*. 2023 Feb 3. PMID: 36732419
 141. Stevens B, **Pollyea DA**. Venetoclax response prediction in acute myeloid leukemia: are we *Finnish*-ed with uncertainty? *Haematologica*. 2023 Feb 16. PMID: 36794503
 142. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, **Pollyea DA**, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. *J Clin Oncol*. 2023 Mar 8:JCO2201794. doi: 10.1200/JCO.22.01794. PMID: 36888930

143. Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, **Pollyea DA**. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. *Haematologica*. 2023 Apr 13. PMID: 37051756
144. Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, **Pollyea DA**, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott BL. Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect Myeloid Disease Registry: Potential Barriers to Care. *Transplant Cell Ther*. 2023 Apr. PMID: 37086851
145. **Pollyea DA**, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2023 May;21(5):503-513. PMID: 37156478
146. Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, **Pollyea DA**, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. *Bone Marrow Transplant*. 2023 Apr 25. PMID: 37185614
147. Canaani J, Frisch A, **Pollyea DA**, Schwartz M, Aumann S, Ganzel C, Haran A, Even-Zohar NG, Shaulov A, Vainstein V, Moshe Y, Ofran Y, Wolach O, Nachmias. Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. *B.Eur J Haematol*. 2023 May 31. PMID: 37254665
148. Khanna V, Azenkot T, Liu SQ, Gilbert J, Cheung E, Lau K, **Pollyea DA**, Traer E, Jonas BA, Zhang TY, Mannis GN. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. *Leuk Res*. 2023 May 29; PMID: 37263072
149. DiNardo CD, De Botton S, **Pollyea DA**, Stone RM, Altman JK, Fathi AT, Limsakun T, Liang M, Choe S, Hossain M, Tron AE, Meng Q, Kapsalis SM, Pandya SS, Stein EM. Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. *Am J Hematol*. 2023 Jun 24. PMID: 37354069

150. Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, **Pollyea DA**, Jordan CT. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. *Cancer Discov*. 2023 Jun 26: PMID: 37358260
151. Shallis RM, Daver N, Altman JK, Komrokji RS, **Pollyea DA**, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. *Lancet Haematol*. 2023 Sep;10(9):e767-e776. Epub 2023 Aug PMID: 37572683
152. Winters AC, **Pollyea DA**. Molecular measurable residual disease: staring at red herrings. *Haematologica*. 2023 Aug 17. PMID: 37584293
153. Gurule NJ, Malcolm KC, Harris C, Knapp JR, O'Connor BP, McClendon J, Janssen WJ, Lee FFY, Price C, Osaghae-Nosa J, Wheeler EA, McMahon CM, Pietras EM, **Pollyea DA**, Alper S. Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis. *Leukemia*. 2023 Aug 17. PMID: 37591942
154. **Pollyea DA**. Progress and challenges in the acute leukemia field. *Best Pract Res Clin Haematol*. 2023 Dec;36(4):101524. PMID: 38092480
155. Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, **Pollyea DA**. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. *Haematologica*. 2023 Dec 14. PMID: 38105738
156. Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, **Pollyea DA**, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee D, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. *Clin Lymphoma Myeloma Leuk*. 2024 Jan 18. PMID: 38378362
157. Madarang E, Lykon J, Zhao W, Sekeres MA, Bradley T, Chandhok NS, Taylor J, Venugopal S, Koru-Sengul T, Iyer S, Gilbert J, Miller RM, Nanni J, Zacheo I, Mattei A, Al Ali N, Kishtagari A, Marconi G, Sallman DA, **Pollyea DA**, Savona MR, Papayannidis C, Komrokji R, Watts J. Venetoclax and Hypomethylating Agents in

Octo- and Nonagenarians with Acute Myeloid Leukemia. *Blood Neoplasia*, 2024. ISSN 2950-3280, <https://doi.org/10.1016/j.bneo.2024.100016>.

158. Sheth AI, Althoff MJ, Tolison H, Engel K, Amaya ML, Krug AE, Young TN, Minhajuddin M, Pei S, Patel SB, Winters A, Miller R, Shelton IT, St-Germain J, Ling T, Jones CL, Raught B, Gillen AE, Ransom M, Staggs S, Smith CA, **Pollyea DA**, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. *Cancer Discov*. 2024 May 24. PMID: 38787341
159. Fang J, Bosma G, Aisner D, McMahon C, Amaya M, Schwartz M, Kaiser J, Abbott D, Pan Z, Schowinsky J, Pang C, Gutman JA, **Pollyea DA**. White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia. *Leuk Lymphoma*. 2024 Jun. PMID: 38814858
160. Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, **Pollyea DA**, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. *Haematologica*. 2024 Jun 27. PMID: 38934082
161. Marvin-Peek J, Gilbert JS, **Pollyea DA**, DiNardo CD. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go? *Am J Hematol*. 2024 Jul 17. PMID: 39016070
162. Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, **Pollyea DA**. Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. *Blood*. 2024 Aug 12. PMID: 39133921
163. Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, **Pollyea DA**, Gutman JA. Outcomes of haplo-cord versus dual cord transplants: a single-center retrospective analysis. *Transplant Cell Ther*. 2024 Aug 16. PMID: 39154914
164. Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, Bosma G, **Pollyea DA**, McMahon CM. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. *Leuk Lymphoma*. 2024 Sep 4:1-3. PMID: 39229898
165. Lachoweiz CA, Ravikumar VI, Othman J, O'Nions J, Peters DT, McMahon C, Swords R, Cook R, Saultz JN, Tyner JW, Dillon RJ, Zeidner JF, **Pollyea DA**. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. *Blood*. 2024 Nov 1. PMID 39486083

Book Chapters and Other Media

1. **Daniel A. Pollyea**. *Thrombocytopenia in Critically Ill Patients*. Just the Facts: Critical Care. Hall, J.B., Hogarth, D.K., Schmidt, G.A. (editors); 2006.
2. Koen van Besien, **Daniel A. Pollyea** and Andrew S. Artz. *Second Allogeneic Transplantation: Outcomes and Indications*. Allogeneic Stem Cell Transplantation: Clinical Research and Practice, 2nd Edition. Judith Karp, ed., 2008.
3. **Daniel A. Pollyea** and Jeffrey T. Schowinsky. *Atypical CML and Chronic Neutrophilic Leukemia*. Managing Myeloproliferative Neoplasms: A Case-Based Approach. Cambridge University Press (Publication pending).
4. Vignesh Narayanan and **Daniel A. Pollyea**. *Hematological Malignancies*. ENT Secrets. (Publication pending)
5. Audio Digest Internal Medicine Board Review: Hematopoetic Stem Cells and their Disorders. May 15, 2014.
6. Continuing Medical Education Faculty, "Clinical Impact of AML Tumor Genomics." (<http://www.cmeuniversity.com/course/disclaimer/111111>)
7. "Professional Courtesy." Essay published in "On Being a Doctor" series of the Annals of Internal Medicine. April 26, 2022.

Scientific Abstracts: Oral Presentations

1. **Pollyea DA**, Kohrt HE, Gallegos L, Zhang B, Figueroa M, Melnick A, Berube C, Coutre SE, Gotlib JR, Liedtke M, Mitchell BS, Medeiros BC. Sequential Azacitidine and Lenalidomide in Elderly Acute Myeloid Leukemia: Completed Results of the Phase I Study. *American Society of Clinical Oncology Conference*, June 4-8, 2011.
2. Maxson JE, Gotlib J, **Pollyea DA**, Fleischman AG, Agarwal A, Luty SB, Abel M, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Collins RH, Pond JB, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I Mutation Found in Chronic Neutrophilic Leukemia Removes an O-Linked Glycosylation Site and Increases Receptor Dimerization. *American Society of Hematology Conference*, December 7-10, 2013.
3. Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, **Pollyea DA**. Chronic Graft Versus Host Disease and Immunosuppression Burden is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. *American Society for Blood and Marrow Transplantation Conference*, February 27, 2014.

4. Konopleva M, **Pollyea DA**, Potluri J, Chyla BJ, Busman T, McKeegan E, Salem A, Zhu M, Ricker JL, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Levenson JD, Humerickhouse RA, Mabry M, Stone RM, Kantarjian HM, Letai AG. A Phase 2 Study of ABT-199 in Patients with Acute Myelogenous Leukemia. *American Society of Hematology Conference*, December 7, 2014.
5. Stein E, Altman JK, Collins R, DeAngelo DJ, Fathi AT, Flinn I, Frankel A, Levine RL, Medeiros BC, Patel M, **Pollyea DA**, Roboz GJ, Sone RM, Swords RT, Tallman MS, Agresta S, Fan B, Yang H, Yen K, de Botton S. AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies. *American Society of Hematology Conference*, December 7, 2014.
6. Riedel S, Haladyna J, Bezzant M, Stevens B, **Pollyea DA**, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T, Bernt KM. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin. *American Society of Hematology Conference*, December 9, 2014.
7. Stein E, Tallman M, **Pollyea DA**, Flinn IW, Fathi AT, Stone RM, Levine RL, Agresta S, Schenkein D, Yang H, Fan B, Yen K, De Botton S. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. *American Association for Cancer Research Conference*, April 6, 2014.
8. Agresta S, Stein EM, Tallman MS, Levine RL, Yua H, Yen K, Fan B, Flinn IW, Fathi AT, Stone RM, DeAngelo DJ, DeBotton S, **Pollyea DA**. A phase I study of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. *European Hematology Association Conference*, June 12-15, 2014.
9. **Pollyea DA**, De Botton S, Fathi AT, Stein EM, Tallman MS, Agresta S, Bowden C, Colby K, Fan B, Goldwasser M, Prah M, Yang H, Yen K, Stone RM. Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies. *EORTC-NCI-AACR Symposium*, November 18-21, 2014.
10. Stein EM, DiNardo C, Altman JK, Collins R, DeAngelo DJ, Kantarjian HM, Sekeres MA, Fathi AT, Flinn IW, Frankel AE, Levine RL, Medeiros BC, Patel MR, **Pollyea DA**, Roboz GJ, Stone RM, Swords RT, Tallman MS, Yen K, Attar EC, Xu Q, Tosolini A, Mei J, Thakurta A, Knight RD, De Botton S. Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a

Phase 1/2 Trial. American Society of Hematology Conference, December 6, 2015.

11. DiNardo C, **Pollyea DA**, Pratz K, Thirman MJ, Letai A, Frattini M, Jonas B, Levenson J, Zhu M, Dunbar M, Falotico N, Kirby R, Agarwal S, Mabry M, Potluri J, Humerickhouse RA, Kantarjian HM, Konopleva M. A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are \geq to 65 Years and Not Eligible for Standard Induction. American Society of Hematology Conference, December 6, 2015.
12. Riedel S, Haladyna J, Stevens B, Jordan CT, **Pollyea DA**, Armstrong SA, Wei Q, Ernst P, Neff T, Bernt KM. Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia. American Society of Hematology Conference, December 6, 2015.
13. Pei S, Minhajuddin M, Stevens BM, Adane B, Khan N, D'alessandro A, Nemkov T, Hansen KC, **Pollyea DA**, Jordan CT. Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function. American Society of Hematology Conference, December 7, 2015.
14. DiNardo CD, de Botton S, Stein EM, Roboz GJ, Swords RT, **Pollyea DA**, Fathi AT, Collins R, Altman JK, Flinn IW, Mannis GN, Mims AS, Foran JM, Pigneux A, Prince GT, Uy GL, Tallman MS, Kantarjian HM, Liu H, Attar EC, Sacolick J, Yen K, Hurov JB, Choe S, Wu B and Stone RM. Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. American Society of Hematology Conference, December 5, 2016.
15. Stein EM, Fathi AT, DiNardo CD, **Pollyea DA**, Swords RT, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Tosolini A, Xu Q, Amatangelo M, Gupta I, Knight RD, De Botton S, Tallman MS, Kantarjian HM. Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (*IDH2*) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes. American Society of Hematology Conference, December 4, 2016.
16. Stein EM, DiNardo CD, **Pollyea DA**, Fathi AT, Roboz GJ, Altman JK, Stone RM, Flinn IW, Kantarjian HM, Collins R, Patel MR, Stein A, Sekeres NA, Swords RT, Medeiros BC, Knight RD, Agresta S, de Botton S, Tallman MS. Enasidenib (AG0221) in mutant IDH2 relapsed or refractory acute myeloid leukemia: Results of a phase 1 dose escalation and expansion study. European Hematology Association annual meeting, June 23, 2017.
17. Pratz K, **Pollyea DA**, Jonas BA, Pullarkat V, Wei A, Arellano M, Becker PS, Frankfurt O, Thirman M, Pigneux A, Recher C, Seymour JF, Dvorak N, Xu T,

Humerickhouse R, Mabry M, Potluri J, Letai A, DiNardo C. Safety and efficacy of venetoclax in combination with decitabine or azacitidine in treatment naïve, elderly patients with AML. European Hematology Association annual meeting, June 24, 2017.

18. George TI, Foucar K, **Pollyea DA**, Erba HP, Thompson MA, Roboz GJ, Pagel JM, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. Antecedent Conformity of Diagnostic and Molecular Testing Patterns in Clinical Practice for Newly Diagnosed Acute Myeloid Leukemia With American Society of Hematology and College of American Pathologists Guidelines. American Society for Clinical Pathology annual meeting, September 7, 2017.
19. DiNardo CD, De Botton S, Stein EM, Roboz GJ, Mims AS, **Pollyea DA**, Swords R, Altman JK, Collins RH, Mannis GN, Uy GL, Donnellan W, Pigneux A, Fathi AT, Stein AS, Erba HP, Prince GT, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Yen K, Kapsalis SM, Liu H, Goldwasser M, Agresta S, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study. American Society of Hematology Conference, December 11, 2017.
20. Stein EM, DiNardo CD, Mims AS, Savona MR, Pratz K, Stein AS, Fathi AT, Stone RM, **Pollyea DA**, Odenike O, Löwenberg R, Döhner H, Schiller G, Gupta IV, Nabhan S, Zhang V, Almon C, Cooper M, Tallman MS. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial. American Society of Hematology Annual Meeting, December 11, 2017.
21. Daver N, **Pollyea DA**, Yee KWL, Fenaux P, Brandwein JM, Vey N, Martinelli G, Kelly KR, Roboz GJ, Garcia JS¹, Pigneux A, Kshirsagar S, Dail M, Wang J, Mobasher M, Chen L, Hong W, Konopleva M, Andreeff M. Preliminary results from a phase 1b study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory AML. American Society of Hematology Annual Meeting, December 11, 2017.
22. **Pollyea DA**, Tallman MS, De Botton S, DiNardo CD, Kantarjian HM, Collins RH, Stein AS, Xu Q, Tosolini A, Gupta I, Agresta SV, Stein EM. Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant IDH2 AML. American Society of Hematology Annual Meeting, December 11, 2017.
23. **Pollyea DA**, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax with azacitidine for untreated elderly AML patients unfit for induction chemotherapy: single center clinical experience and

mechanistic insights from correlative studies. American Society of Hematology Annual Meeting, December 11, 2017.

24. de Botton S, Stein EM, Stone RM, **Pollyea DA**, Roboz GJ, Altman JK, DiNardo CD, Tu N, Swern AS, Tosolini A, Gupta I, Agresta SV, Fathi AT. Continuing enasidenib treatment for patients with mutant IDH2 relapsed or refractory AML with stable disease may result in improved survival and responses over time. Societe Francaise d'Hematologie Annual Meeting, March 28, 2018, Paris.
25. Pratz K, **Pollyea DA**, Jonas B, Pullarkat V, Wei A, Arellano M, Becker P, Frankfurt O, Thirman M, Pigneux A, Recher C, Seymour J, Dvorak N, Xu T, Humerickhouse R, Mabry M, Potluri J, Letai A, DiNardo C. Safety and efficacy of venetoclax in combination with decitabine or azacitidine in treatment-naïve, elderly patients >65 years with acute myeloid leukemia. *British Society of Hematology Annual Meeting*, April 16-18, Liverpool UK.
26. **Pollyea, DA**, Dinardo CD, de Botton S, Stein E, Roboz GJ, Mims AS, Swords RT, Altman JK, Collins R, Mannis GN, Uy GL, Donnellan WB, Pigneus A, Fathi AT, Liu H, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukemia: results of a phase 1 study. American Society of Clinical Oncology meeting, Chicago June 2, 2018.
27. Dinardo CD, Pratz KW, Potluri J, Pullarkat VA, Jonas BA, Wei AH, Becker PS, Frankfurt O, Xu T, Hong W, Chyla B, **Pollyea DA**, Letai AG. Durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia. American Society of Clinical Oncology Meeting, Chicago June 4, 2018.
28. **Pollyea, DA**, Dinardo CD, de Botton S, Stein E, Roboz GJ, Mims AS, Swords RT, Altman JK, Collins R, Mannis GN, Uy GL, Donnellan WB, Pigneus A, Fathi AT, Liu H, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukemia: results of a phase 1 study. European Hematology Association meeting, Stockholm, June 17, 2018.
29. **Pollyea, DA**, Tallman M, de Botton S, DiNardo CD, Kantarjian H, Collins R, Stein AS, Xu Q, Tosolini A, vdn Oostendorp J, Agresta SV, Stein EM. Enasidenib monotherapy is effective and well tolerated in patients with previously untreated mutant IDH2 AML. European Hematology Association meeting, Stockholm, June 17, 2018.
30. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan WB, Erba HP, Mannis GN, **Pollyea DA**, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman mS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results

from a Phase 1 Dose Escalation and Expansion Study. American Society of Hematology meeting, San Diego, December 3, 2018.

31. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, **Pollyea DA**, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Lersch F, Nabhan S, Choe S, Wang H, Hua L, Almon C, Cooper M, Tallman M S. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. American Society of Hematology meeting, San Diego, December 3, 2018.
32. Daver NG, **Pollyea DA**, Garcia JS, Jonas BA, Yee KWL, Fenaux P, Assouline S, Vey N, Olin R, Roboz GJ, Tafuri A, Visani G, Kirschbrown W, Green, Ma C, Dail M, Wang J, Ott MG, Mobasher M, Phuong P, Hong W, Konopleva MY, Andreeff M. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idas) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. American Society of Hematology meeting, San Diego, December 3, 2018.
33. **Pollyea DA**, Pratz KW, Jonas BA, Letai A, Pullarkat VA, Wei A, Konopleva MY, Recher C, Frankfurt O, Rizzieri D, Xu T, Dail M, Chyla B, Potluri J, DiNardo CD. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. American Society of Hematology meeting, San Diego, December 2, 2018.
34. Jones CL, Stevens BM, D'Alessandro A, Reisz J, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Reinhold D, Smith C, DeGregori J, **Pollyea DA**, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. American Society of Hematology meeting, San Diego, December 1, 2018.
35. Gerds AT, Scott BL, Greenberg PL, Khaled SK, Lin TL, **Pollyea DA**, Verma A, Dail M, Green C, Ma C, Medeiros BC, Phuong P, Wenger M, Yan M, Donnellan WB. PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. American Society of Hematology meeting, San Diego, December 2, 2018.
36. **Pollyea DA**, Jones CL, Stevens BM, Pei S, D'Alessandro A, Culp-Hill R, Abbott D, Hammes A, Dugan J, Gutman JA, Purev E, Smith C, Jordan CT. Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. American Society of Hematology meeting, San Diego, December 2, 2018.

37. Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, **Pollyea DA**, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia. American Society of Hematology meeting, San Diego, December 3, 2018.
38. Jones CL, Stevens BM, Culp-Hill R, Nemkov T, D'Alessandro A, Pei S, **Pollyea DA**, Jordan CT. Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism. American Society of Hematology meeting, San Diego, December 2, 2018.
39. Ye H, Adane B, Khan N, Minhajuddin M, Stevens BM, **Pollyea DA**, Jordan CT. Subversion of Systemic Glucose Metabolism As a Mechanism to Support the Growth of Leukemia Cells. American Society of Hematology meeting, San Diego, December 3, 2018.
40. Daver NG, Garcia JS, Jonas BA, Kelly KR, Assouline S, Brandwein JM, Fenaux P, Olin RL, Martinelli G, Paolini S, Pigneux A, **Pollyea DA**, Powell BL, Roboz GJ, Tafuri A, Vey N, Visani G, Yee KWL, Dail M, Green C, Kirschbrown WP, Hong W, Ott MG, Onishi M, Wang J, Konopleva MY, Andreeff M. Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. American Society of Hematology annual meeting, Orlando, December 7, 2019.
41. Zeidan AM, **Pollyea DA**, Garcia JS, Brunner A, Roncolato F, Borate U, Odenike O, Bajel AR, Watson AM, Götze K, Nolte F, Tan PT, Hong W, Dunbar M, Zhou Y, Gressick L, Ainsworth W, Harb J, Salem AH, Hayslip J, Swords R. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. American Society of Hematology annual meeting, Orlando, December 9, 2019.
42. Pratz KW, DiNardo CD, Arellano ML, Letai AG, Thirman M, Pullarkat VA, Roboz GJ, Becker PS, Hong W, Jiang Q, Hayslip J, Potluri J, **Pollyea DA**. Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies. American Society of Hematology annual meeting, Orlando, December 7, 2019.
43. Pei S, **Pollyea DA**, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, Hammes A, Abbott D, Myers JR, Ashton JM, Gutman JA, Purev E, Ramsey HE, Savona MR, Fesik SW, Smith C, Jordan CT. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy. American Society of Hematology annual meeting, Orlando, December 7, 2019.

44. **Pollyea DA**, Winters A, Jordan CT, Smith C, Gutman JA. Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Therapy. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
45. **Pollyea DA**, Dinardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith D, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla BJ, Potluri J, Ridgeway JA, Kantarjian HM. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with *IDH 1/2* Mutations. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
46. **Pollyea DA**, Pratz KW, Wei AH, Pullarkat VA, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. Outcomes in Patients with Poor-Risk Cytogenetics With or Without PT43 Mutations Treated with Venetoclax Combined with Hypomethylating Agents. American Society of Hematology Annual Meeting, Atlanta GA, December 11, 2021.
47. Minhajuddin M, Ye H, Wintercs AC, Pei S, Khan N, Stevens BM, Adane B, Amaya ML, Inguva A, Krug A, Gasparetto M, Sherbenou DW, **Pollyea DA**, Smith C, Jordan CT. Lysosomal Acid Lipase A (LIPA) Modulates Leukemia Stem Cell Response to Venetoclax/TKI Combination therapy in Blast Phase CML. American Society of Hematology Annual Meeting, Atlanta GA, December 13, 2021
48. Zeidan AM, **Pollyea DA**, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Bonifacio G, Chen C. Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy as Induction for Patients with AML: Retrospective Anayiss of an Electronic Medical Records Database in the US. American Society of Hematology Annual Meeting, Atlanta GA, December 11, 2021.
49. Roboz GJ, Abedi M, Thompson MA, Sekeres MA, **Pollyea DA**, Seiter K, Yu E, Kiselev P, Little M, Fernandez I, DeGutis IS, Erba HP. Treatment Patterns and Survival Outcomes of Patients with AML Who Achieved Remission in the Connect Myeloid Disease Registry. American Society of Hematology Annual Meeting, Atlanta GA, December 12, 2021.
50. Zeidan AM, Borate U, **Pollyea DA**, Brunner AM, Roncolato F, Garcia JS, Filshie RJ, Odenike O, Watson A, Krishnadasan R, Bajel A, Naqvi K, Zha J, Hogdal L, Zhou Y, Hoffman D, Key S, Garcia-Manero G. Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory MDS. American Society of Hematology Annual Meeting, Atlanta GA, December 12, 2021.
51. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, **Pollyea DA**, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Gu L, Tan A, Chao M, O'Hear CE, Lal I, Vyas P, Daver N. Magrolimab in combination with azacitidine for untreated higher-risk MDS: SF9005

phase 1b study results. American Society of Clinical Oncology Annual Meeting, Chicago IL, June 4, 2022.

52. Garcia-Manero G, Bachiashvili K, Amin H, Trae E, **Pollyea DA**, Sallman D, Al-Kali A, Cripe LD, Berdeja JG, Griffiths EA, Mohan SR, Sano Y, Oganessian A, Keer HN, Yacoub A. ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients. American Society of Hematology Annual Meeting, New Orleans, LA, December 11, 2022.
53. Döhner H, Pratz KW, DiNardo CD, Jonas BA, Pullarkat VA, Thirman MJ, Recher C, Schuh AC, Babu S, Dail M, Ku G, Sun Y, Potluri J, Chyla B, **Pollyea DA**. ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. American Society of Hematology Annual Meeting, New Orleans, LA, December 11, 2022.
54. Nadorp B, Lasry A, Loghavi S, Patel R, Kelly B, Walker CJ, LaHaye S, Buss J, Boateng I, Nahmod K, Heyrosa A, Desai H, Langanson A, Abaza H, Procell L, Patel T, Kaffenberger B, Wijeratne S, Guillamot Ruano M, Yeaton A, Cayanan G, Velegraki M, Li Z, Sahasrabudhe KD, Abruzzo LV, **Pollyea DA**, McMahon CM, Shana'Ah A, Byrd JC, Tsirigos A, Mardis ER, Mims A, Aifantis I, Eisfeld AK. The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, San Diego, CA, December 10, 2023.
55. Inguva Sheth A, Engel K, Tolison H, Althoff MJ, Krug A, Amaya ML, Pei S, Young T, Patel SB, Minhajuddin M, Miller R, Shelton I, Vujovic A, Jones CL, Gillen AE, Ransom M, Staggs S, Smith C, **Pollyea DA**, Stevens BM, Jordan CT. Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells. American Society of Hematology Annual Meeting, San Diego, CA, December 10, 2023.
56. Grinblatt DL, Roboz GJ, **Pollyea DA**, Sekeres MA, Scott BL, Seiter K, Zeidan AM, Patel JM, Garcia-Manero G, Komrokji RS, Savona MR, Degutis IS, Kiselev P, Yu E, Heydendael W, Qiu Y, Vergara S, McBride A, Erba HP. Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect[®] Myeloid Registry Study. American Society of Hematology Annual Meeting, San Diego, CA, December 10, 2023.
57. Watts JM, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Abbott D, Amaya ML, Kent A, McMahon CM, Schwartz M, Sekeres MA, Smith C, Venugopal S, Jordan CT, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman J, **Pollyea DA**. Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy. American Society of Hematology Annual Meeting, San Diego, CA, December 9, 2024.

58. Mannis G, Aribi A, Dunavin N, Carraway HE, Saultz JN, Roboz GJ, Jonas BA, Madanat YF, Garcia-Manero G, Jeyakumar D, **Pollyea DA**, Odenike O, Blum W, Schiller GJ, Tabata Y, Valencia D, Huang T, Lin WH, Xiang H, Liao C, DiNardo CD. IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results. American Society of Hematology Annual Meeting, San Diego, CA, December 9, 2024.
59. Lachowicz CA, Zeidner JF, Eckel AM, Peters DT, Fang J, Ashango A, Kaempfer A, Dai F, Eide CA, Kurtz SE, Braun TP, Swords RT, Saultz JN, Tyner JW, **Pollyea DA**. Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML. American Society of Hematology Annual Meeting, San Diego, CA, December 7, 2024.

Scientific Abstracts: Poster Presentations

1. **Pollyea D**, Kim E, Manley C, McCrudden K, Huang J, Yokoi A, Soffer S, Kandel J, and Yamashiro D. TNP-470 Alters but does not inhibit angiogenesis in neuroblastoma. *Proceedings of the Pediatric Academic Society Conference*, April 28-May 1, 2001.
2. **Pollyea D**. Pulse-pancreatitis: A diagnosis of exclusion. *American College of Physicians Annual Associates Meeting*, September 4-5, 2003.
3. **Pollyea D**, Artz A, Stock W, Smith S, Daugherty C, Godley L, Zimmerman T, Odenike O, Thirman M, Rich E, Larson R, Van Besien K. Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell transplantation (RIST). *American Society of Hematology Conference*, December 4-7, 2004.
4. Kline J, **Pollyea D**, Artz A, Stock W, Rich E, Godley L, Zimmerman T, Van Besien K. Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1 H based conditioning regimens. *Tandem Bone Marrow Transplant Meetings*, February 10-14, 2005.
5. **Pollyea DA**, Artz AS, Kocherginsky M, Stock W, Smith SM, Daugherty C, Godley L, Zimmerman T, Odenike OM, Thirman M, Rich E, Larson R, Van Besien K. Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell transplantation. *European Hematology Association 10th Congress*, June 2-5, 2005.
6. **Pollyea D**, Artz A, Stock W, Godley L, Odenike O, Rich E, Smith S, Larson R, Van Besien K. Leukemic relapse after allogeneic stem cell transplantation with a T-cell depleted reduced intensity conditioning (RIST) regimen. *American Society of Hematology Conference*, December 10-13, 2005.

7. Michaelis LC, Joseph L, Lin SP, Kline J, Artz A, **Pollyea D**, Stock W, Rich E, Jones D, Casey B, Van Besien K. Donor chimerism after reduced-intensity allogeneic transplantation for hematologic malignancies and relationship to clinical outcomes. *Tandem Bone Marrow Transplant Meetings*, February 16-20, 2006.
8. **Pollyea D**, Artz A, Stock W, Daugherty C, Godley L, Odenike O, Rich E, Smith S, Zimmerman T, Zhang Y, Huo D, Larson R, Van Besien K. New Cytogenetic Abnormalities are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation. *American Society of Hematology Conference*, December 9-12, 2006.
9. Dinner S, Artz A, Kocherginsky M, Ulaszek J, **Pollyea D**, Godley L, Larson R, Odenike O, Rich E, Stock W, Van Besien K, Wickrema A. Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT). *American Society of Hematology Conference*, December 8-11, 2007.
10. **Pollyea D**, Smith S, Fowler N, Boyd T, Smith A, Sirisawad M, Honigberg L, Hamdy A, Advani R. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. *American Society of Hematology Conference*, December 4-8, 2009.
11. Advani R, Sharman JP, Smith SM, **Pollyea DA**, Boyd TE, Grant BW, Kolibaba KS, Buggy JJ, Hamdy A, Fowler NH. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. *American Society of Clinical Oncology Conference*, June 4-8, 2010.
12. Raval A, **Pollyea DA**, Shridhar KJ, Patel S, Greenberg PL, Mitchell BS. Ribosomal RNA Expression in CD34+ Hematopoietic Progenitor Cells Inversely Correlates With Ribosomal DNA Methylation in Myelodysplastic Syndromes. *American Society of Hematology Conference*, December 4-7, 2010.
13. **Pollyea DA**, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS. A Novel Missense Mutation in an MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes. *American Society of Hematology Conference*, December 4-7, 2010.
14. **Pollyea DA**, Kohrt HE, Gallegos L, Berube C, Coutre S, Gotlib JR, Liedtke M, Mitchell BS, Medeiros BC. A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia. *American Society of Hematology Conference*, December 4-7, 2010.
15. **Pollyea DA**, Kohrt HE, Rajwanshi R, Gallegos L, Berube C, Coutre S, Gotlib JR, Liedtke M, Mitchell BS, Medeiros BC. An Early Phase Study of Azacitidine and

Lenalidomide for Untreated Elderly Acute Myeloid Leukemia Patients. *American Society of Clinical Oncology Conference*, June 4-8, 2010.

16. **Pollyea DA**, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Godley L, Medeiros BC. 2-Hydroxyglutarate in *IDH* Mutant AML Patients: Predicting Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels. *American Society of Hematology Conference*, December 10-13, 2011.
17. **Pollyea DA**, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS and Medeiros BC. Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. *American Society of Hematology Conference*, December 8-11, 2012.
18. **Pollyea DA**, Kohrt HE, Yang J, Chang ET, Gomez SL, Clarke CA. Acute Leukemia in Hispanic Americans: Incidence and Incidence Rate Differences by Nativity. *American Society of Hematology Conference*, December 8-11, 2012.
19. **Pollyea DA**, Gore L, Gutman J, Eckhardt SG, Hagelstrom N, Coutre S, Thirman M, Byrd J. A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Targeted Anticancer Therapy Conference*, March 4-6, 2013. Paris, France.
20. Gasparetto M, Jordan CT, Minhajuddin M, **Pollyea DA**, Vasilou V, Reigan P, Humphries RK, Smith CA. ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May be Exploited to Treat AML. *American Society of Hematology Conference*, December 7-10, 2013.
21. **Pollyea DA**, Coutre S, Gore L, Adler N, Harris P, Phelps MA, Johnson AJ, Ling Y, Li H, Gutman JA, Byrd JC. A Dose Escalation Study of Ibrutinib for Relapsed and Refracotry Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *American Society of Hematology Conference*, December 6, 2014.
22. **Pollyea DA**, Smith CA, Nguyen VH, Fullerton A, Schatz D, Bedrick EJ, Gutman JA. Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study. *American Society of Hematology Conference*, December 8, 2014.
23. Gasparetto M, Pei S, Minhajuddin M, **Pollyea DA**, Vasiliou V, Humphries RK, Jordan CT, Smith CA. Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance. *American Society of Hematology Conference*, December 7, 2014.
24. Steensma DP, Abedi M, Attar EC, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X, Maciejewski JP, **Pollyea DA**, Roboz GJ, Savona M, Scott BL, Sekeres

MA, Thompson MA, Zernovak O, Sugrue MM, Swern AS, Nifenecker M, Erba HP. Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. *American Society of Clinical Oncology Conference*, May 30-June 3, 2014.

25. Cortes J, O'Connell A, Shaik MN, Cesari R, Abbattista A, Woolfson A, **Pollyea DA**, Savona M. Phase IB study of PF-04449913, a hedgehog inhibitor, in combination with low-dose cytarabine or intensive chemotherapy, in AML or high-risk MDS. *European Hematology Association Conference*, June 12-15, 2014.
26. Gutman JA, Denoncourt E, Schatz D, Smith C, **Pollyea DA**. A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Transplantation. *American Society for Blood and Marrow Transplantation*, February 11-15, 2015.
27. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Maciejewski J, **Pollyea DA**, Roboz GJ, Savona M, Scott B, Sekeres M, Thompson MA, Sugrue MM, Swern AS, Nifenecker M, Erba H MD. Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. *The 13th International Symposium on Myelodysplastic Syndromes*, April 29-May 2, 2015.
28. DiNardo C, de Botton, **Pollyea DA**, Stein EM, Fathi AT, Roboz GJ, Collins R, Swords RT, Flinn IW, Altman JK, Tallman MS, Kantarjian HM, Derti A, Goldwasser M, Prah M, Wu B, Yen K, Agresta S, Stone RM. Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. *American Society of Hematology Conference*, December 5, 2015.
29. Nooruddin Z, Robinson W, **Pollyea DA**, Gutman JA, Smith C, Pan Z, Jordan CT, Rabinovitch R, Schowinsky J, Lu X, Ney D, Kamdar M. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. *American Society of Hematology Conference*, December 5, 2015.
30. Stevens BM, **Pollyea DA**, Khan N, Jordan CT. Characterization and Targeting of Myelodysplastic Syndrome Stem Cells. *American Society of Hematology Conference*, December 7, 2015.
31. **Pollyea DA**, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA, Arellano ML, Frattini MG, Kantarjian HM, Chyla B, Zhu M, Potluri J, Humerickhouse R, Mabry MH, Konopleva M, Pratz KW. Results of a Phase 1b Study of Venetoclax Plus Decitabine or Azacitidine in Untreated Acute Myeloid Leukemia Patients ≥ 65

Years Ineligible for Standard Induction Therapy. *American Society of Clinical Oncology Conference*, June 6, 2016.

32. **Pollyea DA**, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA, Arellano ML, Frattini MG, Kantarjian HM, Chyla B, Zhu M, Potluri J, Humerickhouse R, Mabry MH, Konopleva M, Pratz KW. Results of a Phase 1b Study of Venetoclax Plus Decitabine or Azacitidine in Untreated Acute Myeloid Leukemia Patients \geq 65 Years Ineligible for Standard Induction Therapy. *European Hematology Association Conference*, June 10, 2016.
33. George TI, Erba HP, Steensma DP, **Pollyea DA**, Abedi M, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji RS, Maciejewski JP, Revicki D, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Thompson MA, Fliss A, Swern AS, Nifenecker M, Kiselev P, Sugrue MM, Foucar K. Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT[®] Myelodysplastic Syndromes (MDS) and AML Disease Registry. *American Society of Hematology Conference*, December 4, 2016.
34. Nooruddin Z, Pan Z, Gross L, Weitzenkamp D, Haverkos BM, **Pollyea DA**, Gutman JA, Robinson W, Smith C, Schowinsky J, Purev E, Sherbenou DW, Rabinovitch R, Ney D, Jordan CT, Kamdar M. Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes. *American Society of Hematology Conference*, December 4, 2016.
35. Pei S, Minhajuddin M, Adane B, Stevens BM, Khan N, D'alessandro A, Nemkov T, Hansen KC, **Pollyea DA**, Jordan CT. Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia. *American Society of Hematology Conference*, December 3, 2016.
36. Adane B, Ye H, Pei S, Khan N, Minhajuddin M, Stevens BM, Zaberezhnyy V, **Pollyea DA**, Jordan CT. The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis. *American Society of Hematology Conference*, December 5, 2016.
37. Stevens BM, **Pollyea DA**, Khan N, Jordan CT. Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention. *American Society of Hematology Conference*, December 5, 2016.
38. George TI, Erba HP, **Pollyea DA**, Abedi M, Roboz GJ, Thompson MA, Fliss A, Swern AS, Nifenecker M, Kiselev P, Sugrue MM, Foucar K. Current diagnosis patterns for acute myeloid leukemia: Concordance between clinical practice (CONNECT Disease Registry) and WHO 2008 recommendations. 14th International Symposium on Myelodysplastic Syndromes, May 4, 2017.

39. **Pollyea DA**, George TI, Foucar K, Erba HP, Thompson MA, Abedi M, Roboz GJ, Landau DA, Pagel JM, Seiter K, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia enrolled in the CONNECT MDS/AML disease registry. American Society of Clinical Oncology, June 5, 2017.
40. **Pollyea DA**, George TI, Foucar K, Erba HP, Thompson MA, Abedi M, Roboz GJ, Landau DA, Pagel JM, Seiter K, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia enrolled in the CONNECT MDS/AML disease registry. European Hematology Association annual meeting, June 23, 2017.
41. Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, **Pollyea DA**, Ma Weidong, Zeremski M, Shaik MN, O'Connell A, Chan G, Schroder MA. A phase 2 study of glasdegib (PF-04449913) in combination with cytarabine and daunorubicin in untreated patients with AML or high-risk MDS. European Hematology Association annual meeting, June 10, 2017. European Hematology Association annual meeting, June 23, 2017.
42. Drusbosky LM, Hawkins KE, Leather HL, Murthy HS, Farhadfar N, Wingard JR, Norkin M, Brown RA, Hiemenz JW, Castillo P, Horn BN, Kumar A, Singh NK, Kumar C, Vasista S, Abbasi T, Vali S, Tognon CE, Kurtz SE, Druker BJ, Tyner JW, **Pollyea DA**, Cogle CR. A genomic signature predicting venetoclax treatment response in AML identified by protein network mapping and validated by ex vivo drug sensitivity testing. American Society of Hematology Annual Meeting, December 10, 2017.
43. Daver N, **Pollyea DA**, Rizzieri DA, Palmer J, Rampal RK, Dinner S, Bixby DL, Percival MM, Kovacsovics T, Begna KH, Perl AE, Konopleva M, Seitz L, McKinnell J, Johnson DT, Ho W, Cortes JE. A phase 1 study of FLX925, a dual FLT3 and CDK4/6 inhibitor in patients with relapsed or refractory AML. American Society of Hematology Annual Meeting, December 9, 2017.
44. DiNardo CD, **Pollyea DA**, Jonas BA, Konopleva M, Pullarkat V, Wei A, Kantarjian HM, Pigneux A, Recher C, Seymour JF, Dunbar M, Xu T, Mabry M, Potluri J, Pratz K, Letai A. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment naïve, elderly patients with AML. American Society of Hematology Annual Meeting, December 10, 2017.
45. Stevens BM, Winters A, Gutman JA, Fullerton A, Hemenway G, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Tech B, Drusbosky LM, Cogle CR, Hammes A, Jordan CT, **Pollyea DA**. Sequential azacitidine and lenalidomide for patients with relapsed and refractory AML: clinical results and predictive modeling using computational analysis and serial genomics. American Society of Hematology Annual Meeting, December 9, 2017.

46. Stein EM, Stone RM, **Pollyea DA**, Roboz GJ, Altman JK, DiNardo CD, de Botton S, Tu N, Swern AS, Tosolini A, Gupta I, Agresta SV, Fathi AT. Continuing enasidenib treatment for patients with mutant IDH2 relapsed or refractory AML with stable disease may result in improved survival and responses over time. American Society of Hematology Annual Meeting, December 9, 2017.
47. Cogle CR, **Pollyea DA**, Abedi M, Thompson MA, Roboz GJ, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Erba HP. Factors influencing first line therapy of AML patients in the Connect MDS/AML disease registry. American Society of Clinical Oncology, June 4, 2018.
48. Fong CY, Wei AH, Frattini M, Jacoby M, Borate U, Gotze K, Carcia JS, **Pollyea DA**, Holes L, Zhou Y, Fakouhi K, Lverson J, Harb JG, Agarwal SK, Attarchi F, Hong W, Jahn TM, Fenaux P, Garcia-Manero G. Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher risk myelodysplastic syndromes. American Society of Clinical Oncology Meeting, June 4, 2018.
49. Stein EM, Stone RM, **Pollyea DA**, Roboz GJ, Altman JK, DiNardo CD, de Botton S, Tu N, Swern AS, Tosolini A, Gupta I, Agresta SV, Fathi AT. Continuing enasidenib treatment for patients with mutant IDH2 relapsed or refractory AML with stable disease may result in improved survival and responses over time. European Hematology Association, Stockholm, Sweden, June 16, 2018.
50. Strickland SA, Chyla B, Popovic R, Bhatena A, Dail M, Sun Y, Wei AH, Fiedler W, Prtaz K, Hayslip J, Potluri J, DiNardo CD, **Pollyea DA**. Cytogenetic and molecular drivers of outcome with venetoclax based combination therapies in treatment naïve elderly patients with AML. European Hematology Association, Stockholm, Sweden, June 16, 2018.
51. Cortes JE, Heidel F, Fiedler W, Smith BD, Robak T, Fernandez P, Candoni A, Leber B, Sekeres MA, **Pollyea DA**, Zeremski M, Ma W, O'Brien T, O'Connell A, Chan G, Heuser M. Glasdegib improved overall survival in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who achieved complete remission (CR) and those who did not achieve CR. European Hematology Association, Stockholm, Sweden, June 16, 2018.
52. Strickland SA, Chyla B, Popovic R, Bhatena A, Dail M, Sun Y, Wei AH, Fiedler W, Prtaz K, Hayslip J, Potluri J, DiNardo CD, **Pollyea DA**. Cytogenetic and molecular drivers of outcome with venetoclax based combination therapies in treatment naïve elderly patients with AML. Uruguayan Congress of Hematology, Montevideo, Uruguay, October 19, 2018.
53. Mukherjee S, Abedi M, Erba HP, **Pollyea DA**, Roboz GJ, Thompson MA, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Cogle CR. Healthcare Resource

Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect MDS/AML Disease Registry. American Society of Hematology annual meeting, December 3, 2018.

54. Stevens BM, Winters A, Abbasi T, Singh NK, Ullal YS, Kumari I, Tyagi A, Alam A, Lunkad N, Drusbosky LM, Cogle CR, Vali S, **Pollyea DA**. WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML). American Society of Hematology annual meeting, San Diego, CA. December 1, 2018.
55. Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz J, Ye H, Khan N, Minhajuddin M, DeGregori J, **Pollyea DA**, Jordan CT. Cysteine and Cystine Depletion Targets Leukemia Stem Cells. American Society of Hematology annual meeting, San Diego, CA. December 2, 2018.
56. Cortes JE, Merchant A, Jamieson C, **Pollyea DA**, Heuser M, Chan G, Wang P, Ching KA, Johnson JA, O'Brien T. Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia. American Society of Hematology annual meeting, San Diego, CA. December 2, 2018.
57. Sharma P, Purev E, Haverkos BM, **Pollyea DA**, Smith C, Kamdar M, Sherbenou DW, Mark TM, Forsberg PA, Gutman JA. Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation. American Society of Hematology annual meeting, San Diego, CA. December 3, 2018.
58. Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant. American Society of Hematology annual meeting, San Diego, CA. December 1, 2018.
59. Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Swords RT, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosloini A, Zu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Enasidenib induces durable hematologic responses in patients with mutant IDH2 myelodysplastic syndromes. International Symposium on MDS, Copenhagen, Denmark. May 11, 2019.
60. Sallman DA, Donnellan WB, Asch AS, Lee DJ, Al Malki M, Marcucci G, **Pollyea DA**, Kambhampati S, Komrokji RS, Van Elk J, Lin M, Agoram B, Chen HY, Volkmer J, Takimoto CHM, Chao M, Vyas P. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients:

Initial phase 1b results. American Society of Clinical Oncology, Chicago IL. June 3, 2019.

61. Roboz GJ, Dinardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Erba HP, **Pollyea DA**, Stein AS, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Fan B, Liu H, Wu B, Attar EC, Stone RM. Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study. American Society of Clinical Oncology, Chicago IL. June 3, 2019.
62. Al-Homsi AS, Purev E, Lewalle P, Abdul-Hay M, **Pollyea DA**, Salaroli A, Lequertier T, Alcantar-Orozco, E, Borghese F, Lonz C, Braun N, Renard F, Flament A, Moors I, Kerre T. Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. American Society of Hematology Annual Meeting. Orlando, December 9, 2019.
63. Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema L, Macero D, Hirose A, Boggs C, Falco A, Monson N, Rahkola S, Wright S, D'Ovidio T, Smith C, Jordan CT, **Pollyea DA**. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy. American Society of Hematology Annual Meeting. Orlando, December 8, 2019.
64. Pratz KW, We AH, **Pollyea DA**, Jonas BA, Fiedler W, Recher C, Hong W, Potluri J, Miller C, Roboz GJ. Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. American Society of Hematology Annual Meeting. Orlando, December 9, 2019.
65. Kent A, Vasu S, Schatz D, Monson N, Devine S, Smith C, Gutman JA, **Pollyea DA**. A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse. American Society of Hematology Annual Meeting. Orlando, December 7, 2019.
66. Jones CL, Stevens BM, Culp-Hill R, Dalessandro A, Krug A, Goosman M, Pei S, **Pollyea DA**, Jordan CT. Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine. American Society of Hematology Annual Meeting. Orlando, December 7, 2019.
67. Gutman JA, Sharma P, Purev E, Smith C, Winters A, Hammes A, Loken MR, **Pollyea DA**. Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and

MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy, American Society of Hematology Annual Meeting. Orlando, December 9, 2019.

68. Jonas, BA, DiNardo CD, Pratz K, Wei A, Hong W, Chyla B, Duan Y, Potluri J, Werner M, **Pollyea DA**. Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia. American Society of Clinical Oncology Annual Meeting. Virtual presentation, June 2020.
69. Heuser M, Robak T, Montesinos P, Leber B, Fiedler WM, **Pollyea DA**, Brown A, O'Connell A, Ma W, Chan G, Cortes JE. Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up. American Society of Clinical Oncology Annual Meeting. Virtual presentation, June 2020.
70. George T, Patel JL, Abedi M, Cogle CR, Erba HP, Garcia-Manero G, Grinblatt DL, Kiselev P, Komrokji RS, Louis CU, Maciejewski JP, Nifenecker M, **Pollyea DA**, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Foucar K. Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry. American Society of Clinical Oncology Annual Meeting. Virtual presentation, June 2020.
71. Huang JQ, Academia E, **Pollyea DA**, Gutman JA, Hammes A, Chase S, O'Bryant CL, Kaiser J. Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN). American Society of Clinical Oncology Annual Meeting. Virtual presentation, June 2020.
72. Zeidan AM, **Pollyea DA**, Garcia JS, Brunner AM, Roncolato F, Borate U, Odenike O, Bajel A, Watson AM, Gotze K, Note F, Tan P, Al-Ali HK, Hong WJ, Zhou Y, Gressick L, Ainsworth W, Harb J, Popovic R, Salem AH, Hayslip J, Swords R, Garcia-Manero G. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. European Hematology Association Annual Meeting. Virtual Presentation, June 2020.
73. Jonas BA, DiNardo CD, Pratz K, Wei AH, Stricklan SA, Hong WJ, Chyla B, Duan Y, Potluri J, Werner M, **Pollyea DA**. Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia. European Hematology Association Annual Meeting. Virtual Presentation, June 2020.
74. Talati C, Asghari H, Abedin S, Lai C, **Pollyea DA**, Xavier M, Edwards W, Zeidner J, Muluneh B, Choi M, Bul CN, Svensson A, Key S, Marshall TS, Cloutier M, Ma E, Montez M, Goldberg AD. Treatment patterns and outcomes of newly diagnosed acute myeloid leukemia patients receiving venetoclax combinations vs. other

therapies: results from the AML real world evidence (ARC) initiative. European Hematology Association Annual Meeting. Virtual Presentation, June 2020.

75. Sallman DA, Al-Homsi AS, Davila ML, Kerre T, Moors I, Poire X, Havelange V, Lewalle P, **Pollyea DA**, MD⁶, Wang ES, Blum W, Demoulin B, Sotiropoulou PA, Alcantar-Orozco E, Breman E, Dheur M, Braun N, Lonez C, Gilham DE, Flament A, Lehmann FF. Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
76. George TI, Abedi M, Cogle CR, Erba HP, Garcia-Manero G, Grinblatt DL, Kiselev P, Komrokji RS, Louis CU, Maciejewski JP, Nifenecker M, **Pollyea DA**, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Patel JL. Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect MDS/AML Disease Registry. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
77. Kent A, **Pollyea DA**, Winters A, Jordan CT, Smith C, Gutman JA. Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
78. Roboz GJ, Cogle CR, **Pollyea DA**, Abedi M, Thompson MA, Nifenecker M, Flick ED, Kiselev P, Louis CU, Little M, DeGutis I, Erba HP. Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect MDS/AML Disease Registry. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
79. **Pollyea DA**, Stahl M, Talati C, Asghari H, Lai C, Abedin S, Zeidner JF, Muluneh B, Xavier M, Edwards W, Wolach O, Moshe Y, Lavie D, Zuckerman T, Choi M, Bui CN, Svensson AE, Kye S, Burne R, Guerin R, Ma E, Montez M, Goldberg A. Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
80. Gutman JA, Winters A, Amaya ML, McMahon CM, Schowinsky J, Abbott D, Hammes A, Pei S, Stevens BM, Jordan CT, Smith C, **Pollyea DA**. Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
81. DiNardo CD, **Pollyea DA**, Konopleva M, Hong K, Huang T, Song A, Wieland E, Woodard P, Liao C, Zhang C, Patel P, Aribi A. A First-in-Human (FIH) Phase 1

Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML). American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.

82. Zeidan AM, **Pollyea DA**, Garcia JS, Brunner AM, Roncolato F, Borate U, Odenike O, Bajel A, Watson A, Götze KS, Nolte F, Tan P, Al-Ali HK, Hong W, Zhou Y, Dunbar M, Gressick L, Ainsworth W, Harb J, Popovic R, Salem AH, Hayslip J, Swords R, Garcia-Manero G. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. American Society of Hematology Annual Meeting. Virtual Presentation, December 2020.
83. Winters AC, Bosma G, Abbott D, Minhajuddin M, Jorda CT, **Pollyea DA**, Gutman JA. Outcomes are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients with Received Venetoclax + Azacitidine versus Intensive Chemotherapy. American Society of Hematology Annual Meeting, Atlanta GA, December 13, 2021.
84. Zeidner JF, Blum W, Fathi AT, **Pollyea DA**, Stephan MM, Carter JD, Heggen C. Barriers to Evidence Based Treatment Decision Making in AML: A Quality Improvement Initiative Across Community Oncology Practices. American Society of Hematology Annual Meeting, Atlanta GA, December 12, 2021.
85. Stevens BW, Winters AC, Minhajuddin M, Amaya ML, McMahon CM, Gutman JA, Smit C, Wang D, Adkins C, Ondracek O, Jordan CT, **Pollyea DA**. Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies. American Society of Hematology Annual Meeting, Atlanta GA, December 12, 2021.
86. Ball S, Jain AG, Aguirre, LEE, Ali M, Bewersdorf JP, Hayden A, Siddon AJ, Lykon J, Madarang E, Sallman DA, Padron E, Sweet K, Lancet JE, Watts JM, Swoboda DM, **Pollyea DA**, Zeidan AM, Komrojki RS. Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent-Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, Atlanta GA, December 12, 2021.
87. Garcia JS, Wolac O, Vachhani P, Zeidner JF, Talati C, **Pollyea DA**, Lai C, Moshe Y, Abedin S, Lavie D, Zucerkman T, Zavier M, Lee S, Edwards W, Chen E, Bui CN, Svensson A, Burne R, Kye S, Matiland J, Ma E, Montez M, Grunspan M, Goldberg AD. Comparative Effectiveness of Venetoclax Combinations vs Other Therapies Among Patients with Newly Diagnosed AML: Results from the AML Real World Evidence Initiative. American Society of Hematology Annual Meeting, Atlanta GA, December 12, 2021.

88. Stevens BM, Engel KL, Gillen AE, Culp-Hill R, D'Alessandro A, Alper S, **Pollyea DA**, Jordan CT. Unique Metabolic Vulnerabilities of MDS Stem Cells. American Society of Hematology Annual Meeting, Atlanta GA, December 11, 2021.
89. Stein EM, DiNardo CD, Fathi AT, Mims AS, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Dohner H, **Pollyea DA**, McCloskey JK, Odenike O, Lowenberg B, Ossenkoppele GJ, Patel P, Roshal M, Frattini MG, Lersch F, Nabhan S, Almon C, Saatcioglu D, Zhang V, Cooper M, Kantarjian H, Tallman MS. Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation. American Society of Hematology Annual Meeting, Atlanta GA, December 11, 2021.
90. Vachhani P, Wolach O, Garcia JS, Zeidner JF, Talati C, **Pollyea DA**, Lai C, Moshe Y, Abdein S, Lavie D, Zuckerman T, Xavier M, Lee S, Chen E, Edwards W, Bui CN, Svensson A, Kye S, Burne R, Maitland J, Ma E, Montez M, Grunspan M, Goldberg AD. Real-World Management of Patients with Newly Diagnosed AML Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative. American Society of Hematology Annual Meeting, Atlanta GA, December 11, 2021.
91. Erba, HP, **Pollyea DA**, Sekeres MA, Garcia-Manerao G, Sieter K, DeGutis IS, Kiselev P, McBride A, Yu E, Roboz GJ. Assessing eligibility for non-intensive chemotherapy randomized clinical trials in patients with newly diagnosed acute myeloid leukemia from the Connect myeloid disease registry. American Society of Clinical Oncology Annual Meeting, Chicago IL, June 4, 2022.
92. Stein E, De Botton S, Pigneux A, McMahon C, Ball B, Brthakur G, Eghtedar A, Kambhampati S, Tache J, Wang ES, Kelley H, Vokert A, Baker K, Fortner-Kang Q, Madigan C, Warlick ED, Roth DA, Kelly M, **Pollyea DA**. Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy. American Society of Clinical Oncology Annual Meeting, Chicago IL, June 4, 2022.
93. McMahon C, Gil K, Amaya ML, Gutman JA, Hayden A, Schwartz M, Bosma G, Abbott D, Stevens BM, Smith C, Jordan CT, **Pollyea DA**. Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, New Orleans, LA. December 11, 2022.
94. Hayden A, Bosma G, Gutman JA, Amaya ML, Abbott D, Smith C, Stevens BM, Jordan CT, **Pollyea DA**, McMahon CM. Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, New Orleans, LA. December 11, 2022.

95. Madarang E, Lykon J, Zhao W, Sekeres MA, Bradley T, Chandhok NS, Taylor J, Koru-Sengul T, Iyer SG, Nanni J, Papayannidis C, Miller RM, Kishtagari A, Savona MR, Gilbert J, **Pollyea DA**, Sallman DA, Al Ali N, Komrokji RS, Watts J. , MD: Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy. American Society of Hematology Annual Meeting, New Orleans, LA. December 11, 2022.
96. Gutman JA, Winters AC, Kent A, Amaya ML, McMahan CM, Smith C, Jordan CT, Stevens BM, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, **Pollyea DA**. Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study. American Society of Hematology Annual Meeting, New Orleans, LA. December 11, 2022.
97. Wolach O, Garcia JS, Desai P, Vachhani P, Zeidner JF, Abedin A, Sweet K, Lai C, Moshe Y, **Pollyea DA**, Xavier M, Nachmias B, Zuckerman T, Lee S, Chen EC, Bathini S, Edwards W, Bui CN, Cheng W, Miller C, Guerin A, Maitland J, Ma E, Montez M, Grunspan G, Goldberg AD. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By *TP53* and *IDH1/2* Mutation: Results from the AML Real World Evidence (ARC) Initiative. American Society of Hematology Annual Meeting, New Orleans, LA. December 10, 2022.
98. Abbott D, Bosma G, McMahan CM, Schwartz M, Gutman JA, **Pollyea DA**. Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.
99. Inguva A, Engel KL, Tolison H, Althoff MJ, Pei S, Amaya ML, Krug A, Minhajuddin M, Jones CL, Gillen AE, Ransom M, Staggs S, **Pollyea DA**, Smith C, Stevens BM, Jordan CT. Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.
100. Kambhampati S, McMahan CM, Eghtedar A, **Pollyea DA**, de Botton S, Pigneux A, Cherry M, Ball BJ, Borthakur G, Cluzeau T, Schiller GJ, Hu B, Volkert A, Gausman JA, Hodgson G, Roth DA, Warlick ED, Kelly MJ, Stein E. Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.
101. Khanna V, Azenkot T, Liu S, Gilbert J, Cheung E, Lau K, **Pollyea DA**, Traer E, Jonas BA, Zhang TY, Mannis GN. Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute

Myeloid Leukemia: A Multi-Center Retrospective Analysis. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.

102. Winters, A, Minhajuddin M, Stevens BM, Major A, Miltgen N, Yuan J, Treece A, Gutman JA, Jordan CT, **Pollyea DA**. Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.
103. Minhajuddin M, Winters AC, Schwartz M, MD, **Pollyea DA**, Jordan CT. Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.
104. Scott BL, Savona MR, Roboz GJ, Seiter K, **Pollyea DA**, DeGutis I, Kiselev P, Yu E, McBride A, Heydendael W, Erba HP. Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT[®] Myeloid Registry Study. American Society of Hematology Annual Meeting, New Orleans, LA. December 12, 2022.
105. Amaya M, McMahon C, Gutman JA, Stevens B, Sohalski C, Tobin J, Smith C, Jordan C, **Pollyea DA**. Results from a phase 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 2023.
106. Pratz KW, DiNardo CD, Arellano M, Thirman M, Pullarkat V, Becker PS, Smith BD, Zhang M, Werner M, Potluri J, **Pollyea DA**. Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax + HMA therapies. European Hematology Association Annual Meeting, Frankfurt. June 2023.
107. Amaya ML, McMahon CM, Schwartz M, Gutman JA, Sohalski S, Tobin J, Gillen AE, Inguva Sheth A, Stevens BM, Smith C, Jordan CT, **Pollyea D**. Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, San Diego. December 10, 2023.
108. Desai P, Garcia JS, Zeidner J, Abedin S, Wolach O, Vachhani P, Moshe Y, **Pollyea DA**, Lai C, LeBlanc TW, Xavier M, Nachmias B, Chen EC, Bathini S, Bhatti I, Bui CN, Guérin A, Burne R, Ma E, Grunspan M, Frankel N, Goldberg AD. Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. American Society of Hematology Annual Meeting, San Diego. December 11, 2023.

109. Tolison H, Duarte C, Peterson G, Bosma GN, Abbott D, George G, **Pollyea DA**, Jordan CT, Amaya ML. A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center. American Society of Hematology Annual Meeting, San Diego. December 10, 2023.
110. Schwartz M, McMahon CM, Amaya ML, Witkowski M, **Pollyea DA**, Gutman JA, Minhajuddin M, Smith C, Jordan CT. Consolidation with Ponatinib Plus Sequential Blinatumomab and Chemotherapy after Low Intensity Dasatinib-Based Induction in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Outcomes from a Single Institution. American Society of Hematology Annual Meeting, San Diego. December 11, 2023.
111. Duarte C, Abbott D, Bosma GN, McMahon CM, Jonathan A Gutman, MD², Marc Schwartz, MD, Pollyea DA, Amaya ML. Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, San Diego. December 11, 2023.
112. Ozga MP, Dvorak-Kornaus KM, Zhao Q, Buss J, Laganson A, Hamp E, Madanat YF, **Pollyea DA**, Stein EM, Zeidner JF, Mardis ER, Eisfeld AK, Mims A. I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy. American Society of Hematology Annual Meeting, San Diego. December 9, 2023.
113. Amaya ML, McMahon CM, Schwartz M, Gutman J, Kent A, Abbott D, Sohalski C, Dell-Martin J, Belachew A, Stevens BM, Jordan CT, **Pollyea DA**. Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, San Diego. December 9, 2024.
114. Duarte C, Abbott D, McMahon CM, Kent A, Schwartz M, Gutman J, **Pollyea DA**, Amaya ML. Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts). American Society of Hematology Annual Meeting, San Diego. December 8, 2024.
115. Gil KB, Borg J, Pereira RM, Sheth A, Rahkola J, Showers W, D'Alessandro A, McMahon CM, **Pollyea DA**, Gillen AE, Amaya ML. STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells. American Society of Hematology Annual Meeting, San Diego. December 8, 2024.
116. Gilbert JS, Connor M, Bosma G, McMahon CM, Amaya ML, Gutman J, Schwartz M, Kent A, Abbott D, **Pollyea DA**. Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia. American Society of Hematology Annual Meeting, San Diego. December 9, 2024.

117. Lachowiez CA, Peters DT, Fang J, Kaempf A, Leonard JT, Newell LF, Gandhi A, Meyers G, Hayes-Lattin B, Maziarz RT, Cook RJ, Traer E, Swords RT, Tyner JW, Zeidner JF, **Pollyea DA**, Saultz JN. Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML. American Society of Hematology Annual Meeting, San Diego. December 9, 2024.
118. Ravikumar VI, Leonard JT, Newell LF, Gandhi A, Meyers G, Hayes-Lattin B, Maziarz RT, Cook RJ, TraerE, Swords RT, Saultz JN, Tyner JW, Heiblig M, Zeidner JF, **Pollyea DA**, Lachowiez CA. *PTPN11* Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax. American Society of Hematology Annual Meeting, San Diego. December 9, 2024.
119. Eckardt J, Srivastava I, Xu Y, Gil KB, Osypuk AA, Pan Z, Schneider MMK, Schulze F, Wendt K, Winter S, Bornhauser M, **Pollyea DA**, Moritz Middeke J. , MD. Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data. American Society of Hematology Annual Meeting, San Diego. December 8, 2024.